[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Corin Ltd\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":283},{"warningLetters":4,"total":282},[5,32,54,77,97,113,135,154,171,193,209,229,246,265],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":27,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":19,"reference_number":19,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},1576,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-03-05T14:20:00Z\">03\u002F05\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-01-25T05:00:00Z\">01\u002F25\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcolgin-inc-670332-01252024\">Colgin, Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations II","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Elizabeth Gardner President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Colgin, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4111 Mint Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dallas\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75237-1605\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Date: January 25, 2024\u003C\u002Fp>\n\n\u003Cp>Case # 670332\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Gardner:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Colgin, Inc., FEI 1610391, at 4111 Mint Way, Dallas, from September 18 to September 21, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your September 28, 2023, response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and\u003Cbr>\n211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture an over-the-counter (OTC) drug product, ChigaRid External Analgesic. You failed to adequately test your incoming components for identity before using the components to manufacture your OTC drug product. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals. Additionally, your firm approved the use of expired raw materials during the production of your ChigaRid External Analgesic drug product.\u003C\u002Fp>\n\n\u003Cp>Your response includes actions that will be taken to improve your component controls. Your response is inadequate because you did not provide supportive documentation, did not consider a retrospective evaluation of potential impact to product currently on the market, and your completion timelines are unclear.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming batch of components for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component batch for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component batch for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component batch.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products manufactured with expired components. The risk assessment should include a summary of all results obtained from testing retain samples from each batch of impacted product. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength,&nbsp;\u003C\u002Fstrong>\u003Cstrong>quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm has not established that your processes used to manufacture ChigaRid External Analgesic drug product are validated.\u003C\u002Fp>\n\n\u003Cp>In your response, you commit to validating your manufacturing process. Your response is inadequate because you did not provide supportive documentation, did not consider a retrospective impact assessment, it lacks completion timelines, and your interim production plans are unclear.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and ensure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A timeline for performing appropriate PPQ for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\n\t\u003Cli>Provide a detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Adequate microbiological testing and appropriate specifications for your finished drug products (21 CFR 211.165(b)).\u003C\u002Fli>\n\t\u003Cli>Any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications are thoroughly investigated, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fli>\n\t\u003Cli>Adequate cleaning and maintenance procedures for the firm’s dedicated manufacturing equipment (21 CFR 211.67(a))\u003C\u002Fli>\n\t\u003Cli>Establishment of an adequate stability program (21 CFR 211.137(a)).\u003C\u002Fli>\n\t\u003Cli>Performance of periodic (i.e., at least annually) product reviews (21 CFR 211.180(e)).\u003C\u002Fli>\n\t\u003Cli>Adequate training for employees engaged in the manufacture, processing, packing, or holding of drug products (21 CFR 211.25(a)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you commit to improving oversight of your QU. However, your response is inadequate because you did not provide supportive documentation, did not consider a retrospective impact assessment, and your interim production plans as well as your completion timeframes are unclear.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure that your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A determination of whether procedures used by your firm are robust and appropriate.\u003C\u002Fli>\n\t\u003Cli>Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003C\u002Fli>\n\t\u003Cli>A complete and final review of each batch and its related information before the QU disposition decision.\u003C\u002Fli>\n\t\u003Cli>Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all drug products.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a \u003Cstrong>(b)(4)\u003C\u002Fstrong>-system audit\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply on company letterhead to Mark W. Rivero, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to mark.rivero@fda.hhs.gov. If you have questions regarding any issues in this letter, please contact Mr. Mark Rivero by e-mail or by phone at (954) 759 - 7718.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>_________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Elizabeth Gardner President\n\nRecipient Title\n\nPresident\n\nColgin, Inc.\n\n4111 Mint Way\n\nDallas, TX 75237-1605\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations II\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nDate: January 25, 2024\n\nCase # 670332\n\nWARNING LETTER\n\nDear Ms. Gardner:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Colgin, Inc., FEI 1610391, at 4111 Mint Way, Dallas, from September 18 to September 21, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your September 28, 2023, response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and\n\n211.84(d)(2)).\n\nYou manufacture an over-the-counter (OTC) drug product, ChigaRid External Analgesic. You failed to adequately test your incoming components for identity before using the components to manufacture your OTC drug product. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals. Additionally, your firm approved the use of expired raw materials during the production of your ChigaRid External Analgesic drug product.\n\nYour response includes actions that will be taken to improve your component controls. Your response is inadequate because you did not provide supportive documentation, did not consider a retrospective evaluation of potential impact to product currently on the market, and your completion timelines are unclear.\n\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\n\nIn response to this letter, provide:\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming batch of components for use in manufacturing.\n\nA description of how you will test each component batch for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component batch for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component batch.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\nA detailed risk assessment addressing the hazards posed by distributing drug products manufactured with expired components. The risk assessment should include a summary of all results obtained from testing retain samples from each batch of impacted product. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n2. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYour firm has not established that your processes used to manufacture ChigaRid External Analgesic drug product are validated.\n\nIn your response, you commit to validating your manufacturing process. Your response is inadequate because you did not provide supportive documentation, did not consider a retrospective impact assessment, it lacks completion timelines, and your interim production plans are unclear.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and ensure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nIn response to this letter, provide the following:\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\nA timeline for performing appropriate PPQ for each of your marketed drug products.\n\nInclude your process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\nProvide a detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\nAdequate microbiological testing and appropriate specifications for your finished drug products (21 CFR 211.165(b)).\n\nAny unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications are thoroughly investigated, whether or not the batch has already been distributed (21 CFR 211.192).\n\nAdequate cleaning and maintenance procedures for the firm’s dedicated manufacturing equipment (21 CFR 211.67(a))\n\nEstablishment of an adequate stability program (21 CFR 211.137(a)).\n\nPerformance of periodic (i.e., at least annually) product reviews (21 CFR 211.180(e)).\n\nAdequate training for employees engaged in the manufacture, processing, packing, or holding of drug products (21 CFR 211.25(a)).\n\nIn your response, you commit to improving oversight of your QU. However, your response is inadequate because you did not provide supportive documentation, did not consider a retrospective impact assessment, and your interim production plans as well as your completion timeframes are unclear.\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure that your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\nA determination of whether procedures used by your firm are robust and appropriate.\n\nProvisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\nA complete and final review of each batch and its related information before the QU disposition decision.\n\nOversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all drug products.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a (b)(4)-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease electronically submit your reply on company letterhead to Mark W. Rivero, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to mark.rivero@fda.hhs.gov. If you have questions regarding any issues in this letter, please contact Mr. Mark Rivero by e-mail or by phone at (954) 759 - 7718.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II\n\n_________________\n\n1 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Colgin, Inc.","colgin-inc-670332-01252024","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcolgin-inc-670332-01252024","2026-10-26T08:08:16.911098+00:00","Warning Letter","Issued","2024-03-05","670332","Drugs","Division of Pharmaceutical Quality Operations II","Ms. Elizabeth Gardner President","2026-08-20T00:15:24.807+00:00","Via Email","2024-01-25",{"id":33,"raw":34,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":19,"letter_url":46,"updated_at":47,"action_type":22,"case_status":23,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":19,"issuing_office":38,"recipient_name":51,"body_fetched_at":52,"delivery_method":53,"recipient_title":19,"reference_number":19,"action_taken_date":48,"medical_device_id":19,"response_letter_date":19},2844,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2022-02-24T20:00:00Z\">02\u002F24\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-24T05:00:00Z\">02\u002F24\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvapor-corner-inc-625765-02242022\">Vapor Corner Inc\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Cathy Summerlin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Vapor Corner Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1111 North Slappey Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Albany\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>31701\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:cathysdome@yahoo.com\"> cathysdome@yahoo.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 24, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Summerlin:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Vapor Corner, Inc manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States The Vapor Corner MBL 12mg\u002F100ml e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 1,100 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200445, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nCathy Summerlin\n\nRecipient Title\n\nOwner\n\nVapor Corner Inc\n\n1111 North Slappey Boulevard\n\nAlbany, GA 31701\n\nUnited States\n\ncathysdome@yahoo.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nFebruary 24, 2022\n\nWARNING LETTER\n\nDear Ms. Summerlin:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Vapor Corner, Inc manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States The Vapor Corner MBL 12mg\u002F100ml e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 1,100 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200445, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Vapor Corner Inc","vapor-corner-inc-625765-02242022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvapor-corner-inc-625765-02242022","2026-10-26T08:10:23.791092+00:00","2022-02-24","625765","Tobacco","Cathy Summerlin","2026-08-20T02:08:57.844+00:00","VIA UPS and Electronic Mail",{"id":55,"raw":56,"subject":62,"body_html":63,"body_text":64,"firm_name":65,"letter_id":66,"created_at":67,"fei_number":19,"letter_url":68,"updated_at":69,"action_type":22,"case_status":23,"posted_date":70,"marcs_cms_no":71,"product_type":72,"closeout_date":19,"issuing_office":60,"recipient_name":73,"body_fetched_at":74,"delivery_method":75,"recipient_title":19,"reference_number":19,"action_taken_date":76,"medical_device_id":19,"response_letter_date":19},3320,[57,58,59,60,61,13,13,13],"\u003Ctime datetime=\"2021-06-01T13:20:00Z\">06\u002F01\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-05-11T04:00:00Z\">05\u002F11\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Futah-cord-bank-llc-614021-05112021\">Utah Cord Bank LLC\u003C\u002Fa>","Office Biological Products Operations – Division 2","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)\u003Cbr \u002F>\r\n","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Eliott D. Spencer, Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Utah Cord Bank LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8675 S Sandy Parkway, Bldg. 110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sandy\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84070\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office Biological Products Operations – Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 11, 2021\u003C\u002Fp>\n\n\u003Cp>[Warning Letter #OBPO 21-614021]\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Spencer:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm, Utah Cord Bank, LLC, located at 8675 S Sandy Parkway, Bldg. 110, Sandy, UT 84070 from February 1-11, 2021. During the inspection, an FDA Investigator documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs)\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>&nbsp;set forth in Title 21, Code of Federal Regulations (CFR) Part 1271 [21 CFR 1271], and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C 264].\u003C\u002Fp>\n\n\u003Cp>The deviations documented on the Form FDA-483, List of Inspectional Observations, were presented to and discussed with you at the conclusion of the inspection. These items of concern include, but are not limited to, the items discussed below. All items below pertain to HCT\u002FPs recovered from donors between May 25, 2005 and February 11, 2021. Following our review of the information collected during the inspection, we identified additional concerns that are also included below.\u003C\u002Fp>\n\n\u003Cp>1.&nbsp; Failure to validate and approve a process according to established procedures where the results of processing cannot be fully verified by subsequent inspections and tests. The validation activities and results must be documented, including the date and signature of the individual(s) approving the validation [21 CFR 1271.230(a)]. For example:\u003C\u002Fp>\n\n\u003Cp>a.&nbsp;&nbsp; &nbsp;You failed to validate your process, which cannot be fully verified, used in the manufacture of HCT\u002FPs to ensure that your process does not cause contamination or cross-contamination and prevents the introduction, transmission or spread of communicable disease through the use of the HCT\u002FP.\u003C\u002Fp>\n\n\u003Cp>b.&nbsp;&nbsp; &nbsp;Processing is defined at 21 CFR 1271.3(ff) and includes testing for microorganisms. &nbsp;You failed to validate your microbiological testing, which cannot be fully verified, used in the manufacture of HCT\u002FPs to ensure that your process prevents the introduction, transmission or spread of communicable disease through the use of the HCT\u002FP.\u003C\u002Fp>\n\n\u003Cp>2.&nbsp;&nbsp;Failure to adequately monitor environmental conditions and provide proper conditions for operations, where environmental conditions could reasonably be expected to cause contamination or cross-contamination of HCT\u002FPs or equipment, or accidental exposure of HCT\u002FPs to communicable disease agents [21 CFR 1271.195(c)]. For example, the steps in processing HCT\u002FPs you described to the investigators during the inspection include exposing the unit of cord blood to the environment by draining the umbilical cord blood from the original collection bag into \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;vials. These conditions could reasonably be expected to cause contamination or cross-contamination of the HCT\u002FPs, however, you do not monitor environmental conditions in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;for the presence of microorganisms.&nbsp;\u003C\u002Fp>\n\n\u003Cp>3.&nbsp;&nbsp;Failure to establish and maintain procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT\u002FPs. You must design these procedures to prevent circumstances that increase the risk of the introduction, transmission, or spread of communicable diseases through the use of HCT\u002FPs [21 CFR 1271.180(a)]. For example, you have not established and maintained procedures that include, but are not limited to the following: &nbsp;\u003C\u002Fp>\n\n\u003Cp>a.&nbsp;&nbsp; &nbsp;Facilities (i.e.: maintenance\u002Frepairs, cleaning, sanitation) [21 CFR 1271.190(d)];\u003Cbr>\nb.&nbsp;&nbsp; &nbsp;Environmental control [21 CFR 1271.195];\u003Cbr>\nc.&nbsp;&nbsp; &nbsp;Equipment (i.e.: maintenance, cleaning, calibration) [21 CFR 1271.200(b)];\u003Cbr>\nd.&nbsp;&nbsp; &nbsp;Verification of supplies and reagents [21 CFR 1271.210];\u003Cbr>\ne.&nbsp;&nbsp; &nbsp;Processing and processing controls [21 CFR 1271.220];\u003Cbr>\nf.&nbsp;&nbsp; &nbsp;Labeling controls [21 CFR 1271.250];\u003Cbr>\ng.&nbsp;&nbsp; &nbsp;Storage [21 CFR 1271.260]; and\u003Cbr>\nh.&nbsp;&nbsp; &nbsp;Receipt, predistribution shipment, and distribution, including release criteria and shipping conditions [21 CFR 1271.265].\u003C\u002Fp>\n\n\u003Cp>4.&nbsp;&nbsp; &nbsp;Failure to maintain records concurrently with the performance of each step required in Subpart D and Subpart C of 21 CFR 1271. The records must identify the person performing the work and the dates of the various entries, and must be as detailed as necessary to provide a complete history of the work performed and to relate the records to the particular HCT\u002FP involved [21 CFR 1271.270(a)]. For example, you have not maintained complete records that include, but are not limited to, the following: &nbsp;\u003C\u002Fp>\n\n\u003Cp>a.&nbsp;&nbsp; &nbsp;Facility cleaning and sanitation [21 CFR 1271.190(d)];\u003Cbr>\nb.&nbsp;&nbsp; &nbsp;Environmental control and monitoring activities [21 CFR 1271.195(d)];\u003Cbr>\nc.&nbsp;&nbsp; &nbsp;Equipment maintenance, cleaning, sanitizing, and calibration [21 CFR 1271.200(e)];\u003Cbr>\nd.&nbsp;&nbsp; &nbsp;Receipt, verification, and lot number of each supply and\u002For reagent used in the manufacture of HCT\u002FPs [21 CFR 1271.210(d)];\u003Cbr>\ne.&nbsp;&nbsp; &nbsp;Storage temperatures [21 CFR 1271.260(e)];\u003Cbr>\nf.&nbsp;&nbsp; &nbsp;Recovery [21 CFR 1271.215];\u003Cbr>\ng.&nbsp;&nbsp; &nbsp;Processing (including sterility testing) [21 CFR 1271.220]; and\u003Cbr>\nh.&nbsp;&nbsp; &nbsp;Complaints [21 CFR 1271.320(b)].\u003C\u002Fp>\n\n\u003Cp>Based on the information obtained during the inspection and stated in your FDA 483 correspondence, it is unclear whether your products are intended for autologous use only, or whether they are also intended for allogeneic use in a first-degree or second-degree blood relative. Please clarify all potential uses of your products. Donor-eligibility determination, Subpart – C of 21 CFR 1271, is based on donor screening and testing for relevant communicable disease agents and diseases (described in §1271.50) and is required for all donors used in HCT\u002FPs except as outlined under §1271.90.\u003C\u002Fp>\n\n\u003Cp>The deviations identified above are not intended to be an all-inclusive list of deficiencies at your facility. &nbsp;It is your responsibility to ensure that your establishment is in compliance with all the applicable requirements of the federal regulations. &nbsp;You are responsible for reviewing your firm’s operations as a whole to ensure that you fully comply with the law.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your letters dated March 5, 2021 and April 16, 2021, in response to the Form FDA 483 issued to you on February 11, 2021. We have reviewed your responses in which you state that you have retained the services of a consultant. However, other than retaining the services of a consultant, your response is silent regarding specific corrective actions to address the violations outlined above. &nbsp;&nbsp;\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations addressed in this letter and prevent their recurrence. &nbsp;Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. &nbsp;If you believe that your product is not in violation of the law, include your reasoning and any supporting information for our consideration. Additionally, include any documentation necessary to show that correction of any of the above-noted violations has been achieved. &nbsp;If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and time frame within which the remaining corrections will be completed.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Marc Jackson, U.S. Food &amp; Drug Administration, Office of Biological Product Operations – Division 2, DFC – BLDG 20 – W 6th Ave &amp; Kipling St., Denver, CO 80225, or emailed to Marc.Jackson@fda.hhs.gov. If you should have any questions, please contact Marc Jackson, Compliance Officer at (303) 236-3083 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>__________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>&nbsp;This letter applies solely to products manufactured for autologous use or, depending on your response to FDA's request at the close of this letter, any products manufactured for allogeneic use in a first-degree or&nbsp;second-degree blood relative. Accordingly, references in this letter to HCT\u002FPs or \"products\" do not include&nbsp;products manufactured by your firm&nbsp;that are not for autologous use or allogeneic use in a first-degree or&nbsp;second-degree blood relative. FDA intends to communicate with Utah Cord Bank, LLC separately&nbsp;regarding these products.&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nEliott D. Spencer, Ph.D.\n\nRecipient Title\n\nPresident\u002FOwner\n\nUtah Cord Bank LLC\n\n8675 S Sandy Parkway, Bldg. 110\n\nSandy, UT 84070\n\nUnited States\n\nIssuing Office:\n\nOffice Biological Products Operations – Division 2\n\nUnited States\n\nMay 11, 2021\n\n[Warning Letter #OBPO 21-614021]\n\nDear Dr. Spencer:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm, Utah Cord Bank, LLC, located at 8675 S Sandy Parkway, Bldg. 110, Sandy, UT 84070 from February 1-11, 2021. During the inspection, an FDA Investigator documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs)1 set forth in Title 21, Code of Federal Regulations (CFR) Part 1271 [21 CFR 1271], and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C 264].\n\nThe deviations documented on the Form FDA-483, List of Inspectional Observations, were presented to and discussed with you at the conclusion of the inspection. These items of concern include, but are not limited to, the items discussed below. All items below pertain to HCT\u002FPs recovered from donors between May 25, 2005 and February 11, 2021. Following our review of the information collected during the inspection, we identified additional concerns that are also included below.\n\n1. Failure to validate and approve a process according to established procedures where the results of processing cannot be fully verified by subsequent inspections and tests. The validation activities and results must be documented, including the date and signature of the individual(s) approving the validation [21 CFR 1271.230(a)]. For example:\n\na. You failed to validate your process, which cannot be fully verified, used in the manufacture of HCT\u002FPs to ensure that your process does not cause contamination or cross-contamination and prevents the introduction, transmission or spread of communicable disease through the use of the HCT\u002FP.\n\nb. Processing is defined at 21 CFR 1271.3(ff) and includes testing for microorganisms. You failed to validate your microbiological testing, which cannot be fully verified, used in the manufacture of HCT\u002FPs to ensure that your process prevents the introduction, transmission or spread of communicable disease through the use of the HCT\u002FP.\n\n2. Failure to adequately monitor environmental conditions and provide proper conditions for operations, where environmental conditions could reasonably be expected to cause contamination or cross-contamination of HCT\u002FPs or equipment, or accidental exposure of HCT\u002FPs to communicable disease agents [21 CFR 1271.195(c)]. For example, the steps in processing HCT\u002FPs you described to the investigators during the inspection include exposing the unit of cord blood to the environment by draining the umbilical cord blood from the original collection bag into (b)(4) vials. These conditions could reasonably be expected to cause contamination or cross-contamination of the HCT\u002FPs, however, you do not monitor environmental conditions in the (b)(4) for the presence of microorganisms.\n\n3. Failure to establish and maintain procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT\u002FPs. You must design these procedures to prevent circumstances that increase the risk of the introduction, transmission, or spread of communicable diseases through the use of HCT\u002FPs [21 CFR 1271.180(a)]. For example, you have not established and maintained procedures that include, but are not limited to the following:\n\na. Facilities (i.e.: maintenance\u002Frepairs, cleaning, sanitation) [21 CFR 1271.190(d)];\n\nb. Environmental control [21 CFR 1271.195];\n\nc. Equipment (i.e.: maintenance, cleaning, calibration) [21 CFR 1271.200(b)];\n\nd. Verification of supplies and reagents [21 CFR 1271.210];\n\ne. Processing and processing controls [21 CFR 1271.220];\n\nf. Labeling controls [21 CFR 1271.250];\n\ng. Storage [21 CFR 1271.260]; and\n\nh. Receipt, predistribution shipment, and distribution, including release criteria and shipping conditions [21 CFR 1271.265].\n\n4. Failure to maintain records concurrently with the performance of each step required in Subpart D and Subpart C of 21 CFR 1271. The records must identify the person performing the work and the dates of the various entries, and must be as detailed as necessary to provide a complete history of the work performed and to relate the records to the particular HCT\u002FP involved [21 CFR 1271.270(a)]. For example, you have not maintained complete records that include, but are not limited to, the following:\n\na. Facility cleaning and sanitation [21 CFR 1271.190(d)];\n\nb. Environmental control and monitoring activities [21 CFR 1271.195(d)];\n\nc. Equipment maintenance, cleaning, sanitizing, and calibration [21 CFR 1271.200(e)];\n\nd. Receipt, verification, and lot number of each supply and\u002For reagent used in the manufacture of HCT\u002FPs [21 CFR 1271.210(d)];\n\ne. Storage temperatures [21 CFR 1271.260(e)];\n\nf. Recovery [21 CFR 1271.215];\n\ng. Processing (including sterility testing) [21 CFR 1271.220]; and\n\nh. Complaints [21 CFR 1271.320(b)].\n\nBased on the information obtained during the inspection and stated in your FDA 483 correspondence, it is unclear whether your products are intended for autologous use only, or whether they are also intended for allogeneic use in a first-degree or second-degree blood relative. Please clarify all potential uses of your products. Donor-eligibility determination, Subpart – C of 21 CFR 1271, is based on donor screening and testing for relevant communicable disease agents and diseases (described in §1271.50) and is required for all donors used in HCT\u002FPs except as outlined under §1271.90.\n\nThe deviations identified above are not intended to be an all-inclusive list of deficiencies at your facility. It is your responsibility to ensure that your establishment is in compliance with all the applicable requirements of the federal regulations. You are responsible for reviewing your firm’s operations as a whole to ensure that you fully comply with the law.\n\nWe acknowledge receipt of your letters dated March 5, 2021 and April 16, 2021, in response to the Form FDA 483 issued to you on February 11, 2021. We have reviewed your responses in which you state that you have retained the services of a consultant. However, other than retaining the services of a consultant, your response is silent regarding specific corrective actions to address the violations outlined above.\n\nYou should take prompt action to correct the violations addressed in this letter and prevent their recurrence. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. If you believe that your product is not in violation of the law, include your reasoning and any supporting information for our consideration. Additionally, include any documentation necessary to show that correction of any of the above-noted violations has been achieved. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and time frame within which the remaining corrections will be completed.\n\nYour response should be sent to the following address: Marc Jackson, U.S. Food & Drug Administration, Office of Biological Product Operations – Division 2, DFC – BLDG 20 – W 6th Ave & Kipling St., Denver, CO 80225, or emailed to Marc.Jackson@fda.hhs.gov. If you should have any questions, please contact Marc Jackson, Compliance Officer at (303) 236-3083 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton Watson\n\nProgram Division Director\n\nOffice Biological Products Operations – Division 2\n\n__________________\n\n1 This letter applies solely to products manufactured for autologous use or, depending on your response to FDA's request at the close of this letter, any products manufactured for allogeneic use in a first-degree or second-degree blood relative. Accordingly, references in this letter to HCT\u002FPs or \"products\" do not include products manufactured by your firm that are not for autologous use or allogeneic use in a first-degree or second-degree blood relative. FDA intends to communicate with Utah Cord Bank, LLC separately regarding these products.","Utah Cord Bank LLC","utah-cord-bank-llc-614021-05112021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Futah-cord-bank-llc-614021-05112021","2026-10-26T08:10:18.701861+00:00","2021-06-01","614021","Biologics","Eliott D. Spencer, Ph.D.","2026-08-20T03:05:47.645+00:00","VIA UNITED PARCEL SERVICE","2021-05-11",{"id":78,"raw":79,"subject":40,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":88,"fei_number":19,"letter_url":89,"updated_at":90,"action_type":22,"case_status":91,"posted_date":92,"marcs_cms_no":93,"product_type":50,"closeout_date":94,"issuing_office":38,"recipient_name":95,"body_fetched_at":96,"delivery_method":53,"recipient_title":19,"reference_number":19,"action_taken_date":92,"medical_device_id":19,"response_letter_date":19},3517,[80,81,82,38,40,13,83,13],"\u003Ctime datetime=\"2021-02-26T14:00:00Z\">02\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-26T05:00:00Z\">02\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvape-corner-inc-613522-02262021\">The Vape Corner, Inc.\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvape-corner-inc-613522-06242021\">\u003Ctime datetime=\"2021-07-09T04:00:00Z\">07\u002F09\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gino Sugapong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>The Vape Corner, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3158 Main St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Diego\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92113\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@thevapecorner.com\"> info@thevapecorner.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Gino Sugapong:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fthevapecorner.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquids are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)).&nbsp; Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of https:\u002F\u002Fthevapecorner.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products for The Vape Corner without a marketing authorization order including: Krunchy Pebbles, Frooty Loops, and Papa Bear.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 100 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be subject to detention and refusal of admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you do not believe that your products are in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fhome\">http:\u002F\u002Fwww.fda.gov\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2101509, in your response and direct your response via email at \u003Ca href=\"mailto:CTPCompliance@fda.hhs.gov\">CTPCompliance@fda.hhs.gov\u003C\u002Fa> and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at \u003Cspan>(301) 796-9235\u003Ca>\u003C\u002Fa>\u003C\u002Fspan> or via email at \u003Ca href=\"mailto:CTPCompliance@fda.hhs.gov\">CTPCompliance@fda.hhs.gov\u003C\u002Fa>.&nbsp;&nbsp;&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nVIA UPS and Electronic Mail\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Phone Ly\u003Cbr>\n7323 Convoy Ct. Ste. B107\u003Cbr>\nSan Diego, California 92111\u003C\u002Fp>\n\n\u003Cp>Domains By Proxy, LLC\u003Cbr>\nThevapecorner.com@domainsbyproxy.com\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>DigitalOcean, LLC\u003Cbr>\nabuse@digitalocean.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nGino Sugapong\n\nThe Vape Corner, Inc.\n\n3158 Main St.\n\nSan Diego, CA 92113\n\nUnited States\n\ninfo@thevapecorner.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Gino Sugapong:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fthevapecorner.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquids are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of https:\u002F\u002Fthevapecorner.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products for The Vape Corner without a marketing authorization order including: Krunchy Pebbles, Frooty Loops, and Papa Bear.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 100 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be subject to detention and refusal of admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you do not believe that your products are in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101509, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nPhone Ly\n\n7323 Convoy Ct. Ste. B107\n\nSan Diego, California 92111\n\nDomains By Proxy, LLC\n\nThevapecorner.com@domainsbyproxy.com\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nDigitalOcean, LLC\n\nabuse@digitalocean.com","The Vape Corner, Inc.","vape-corner-inc-613522-02262021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvape-corner-inc-613522-02262021","2026-10-26T08:10:19.555877+00:00","Closed Out","2021-02-26","613522","2021-07-09","Gino Sugapong","2026-08-20T03:21:05.032+00:00",{"id":98,"raw":99,"subject":40,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":106,"fei_number":19,"letter_url":107,"updated_at":108,"action_type":22,"case_status":23,"posted_date":109,"marcs_cms_no":110,"product_type":50,"closeout_date":19,"issuing_office":38,"recipient_name":19,"body_fetched_at":111,"delivery_method":53,"recipient_title":19,"reference_number":112,"action_taken_date":109,"medical_device_id":19,"response_letter_date":19},672,[100,100,101,38,40,13,13,13],"\u003Ctime datetime=\"2025-09-11T04:00:00Z\">09\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcordova-tobacco-vape-711225-09112025\">Cordova Tobacco &amp; Vape\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2501248\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Cordova Tobacco &amp; Vape\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1204 North Houston Levee Road Suite 113\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cordova\u003C\u002Fspan>, \u003Cspan>TN\u003C\u002Fspan> \u003Cspan>38018\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 11, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Cordova Tobacco &amp; Vape sells and\u002For distributes electronic nicotine delivery system (ENDS) products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States the following ENDS products that lack a marketing authorization order: Fasta Burrst 35000 Frozen Strawberry Banana 5% nicotine.\u003C\u002Fp>\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501248, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2501248\n\nProduct:\n\nTobacco\n\nRecipient:\n\nCordova Tobacco & Vape\n\n1204 North Houston Levee Road Suite 113\n\nCordova, TN 38018\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nSeptember 11, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Cordova Tobacco & Vape sells and\u002For distributes electronic nicotine delivery system (ENDS) products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States the following ENDS products that lack a marketing authorization order: Fasta Burrst 35000 Frozen Strawberry Banana 5% nicotine.\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501248, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","Cordova Tobacco & Vape","cordova-tobacco-vape-711225-09112025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcordova-tobacco-vape-711225-09112025","2026-10-26T08:08:18.166886+00:00","2025-09-11","711225","2026-08-19T16:25:53.107+00:00","ER2501248",{"id":114,"raw":115,"subject":120,"body_html":121,"body_text":122,"firm_name":123,"letter_id":124,"created_at":125,"fei_number":19,"letter_url":126,"updated_at":127,"action_type":22,"case_status":23,"posted_date":128,"marcs_cms_no":129,"product_type":130,"closeout_date":19,"issuing_office":119,"recipient_name":131,"body_fetched_at":132,"delivery_method":133,"recipient_title":19,"reference_number":19,"action_taken_date":134,"medical_device_id":19,"response_letter_date":19},2183,[116,117,118,119,120,13,13,13],"\u003Ctime datetime=\"2023-02-28T14:20:00Z\">02\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-05T05:00:00Z\">01\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcorporate-essentials-llc-645165-01052023\">Corporate Essentials LLC\u003C\u002Fa>","Division of Northeast Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Judson Kleinman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Corporate Essentials LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2 Cranberry Road, Ste. A2\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Parsippany\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07054\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northeast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 5, 2023\u003C\u002Fp>\n\n\u003Cp>Re: CMS# 645165\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Judson Kleinman:\u003C\u002Fp>\n\n\u003Cp>From June 29 to September 22, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Corporate Essentials LLC located at 2 Cranberry Road, Ste. A2, Parsippany, NJ. We also conducted inspections on August 21, 2018, and February 11, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the most recent inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on September 22, 2022.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Liquid chocolate drink, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Liquid chocolate drink, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Feryal Ahmad, Compliance Officer, Division of Northeast Imports, ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) Feryal.Ahmad@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Ahmad via email at Feryal.Ahmad@fda.hhs.gov. Please reference CMS# 645165 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Theresa Smedley\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Judson Kleinman\n\nRecipient Title\n\nOwner and CEO\n\nCorporate Essentials LLC\n\n2 Cranberry Road, Ste. A2\n\nParsippany, NJ 07054\n\nUnited States\n\nIssuing Office:\n\nDivision of Northeast Imports\n\nUnited States\n\nWARNING LETTER\n\nJanuary 5, 2023\n\nRe: CMS# 645165\n\nDear Mr. Judson Kleinman:\n\nFrom June 29 to September 22, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Corporate Essentials LLC located at 2 Cranberry Road, Ste. A2, Parsippany, NJ. We also conducted inspections on August 21, 2018, and February 11, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the most recent inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on September 22, 2022.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including:\n\nLiquid chocolate drink, imported from (b)(4), located in (b)(4)\n\nLiquid chocolate drink, imported from (b)(4), located in (b)(4).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Feryal Ahmad, Compliance Officer, Division of Northeast Imports, ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) Feryal.Ahmad@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Ahmad via email at Feryal.Ahmad@fda.hhs.gov. Please reference CMS# 645165 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTheresa Smedley\n\nActing Program Division Director\n\nDivision of Northeast Imports","Corporate Essentials LLC","corporate-essentials-llc-645165-01052023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcorporate-essentials-llc-645165-01052023","2026-10-26T08:08:18.248595+00:00","2023-02-28","645165","Food & Beverages","Mr. Judson Kleinman","2026-08-20T01:13:24.199+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2023-01-05",{"id":136,"raw":137,"subject":62,"body_html":143,"body_text":144,"firm_name":145,"letter_id":146,"created_at":67,"fei_number":19,"letter_url":147,"updated_at":148,"action_type":22,"case_status":23,"posted_date":149,"marcs_cms_no":150,"product_type":72,"closeout_date":19,"issuing_office":141,"recipient_name":151,"body_fetched_at":152,"delivery_method":75,"recipient_title":19,"reference_number":19,"action_taken_date":153,"medical_device_id":19,"response_letter_date":19},3205,[138,139,140,141,142,13,13,13],"\u003Ctime datetime=\"2021-08-17T13:20:00Z\">08\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-10T04:00:00Z\">08\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Futah-cord-bank-llc-dba-utah-cell-bank-614013-08102021\">Utah Cord Bank LLC dba Utah Cell Bank\u003C\u002Fa>","Office of Biological Products Operations - Division 2","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Eliott D. Spencer, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u002FPresident\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Utah Cord Bank LLC dba Utah Cell Bank\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8675 S. Sandy Parkway, Suite 110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sandy\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84070-6418\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations - Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 10, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter #OBPO 21-614013\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Spencer:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firms, Utah Cord Bank LLC (Utah Cord Bank), dba Utah Cell Bank, and FIOR Bioscience LLC (FIOR Bioscience), co-located at 8675 S. Sandy Parkway, Suite 110, Sandy, UT 84070, conducted between February 1 and February 11, 2021, United States Food and Drug Administration (FDA) investigators documented that you manufacture cellular products for allogeneic use, including: human umbilical cord blood, umbilical cord, and amniotic membrane derived cellular products with the brand names StemVive® and StemMaxx™ (also known as Stemii and Stemshot); a human umbilical cord blood derived product with the brand name StemTru™; and a human umbilical cord derived product with the brand name StemCellect™ (collectively, “your products”).\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> FIOR Bioscience distributes your products directly to health care professionals and medical facilities. These products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to and at the time of the inspection, including information on the FIOR Bioscience website, https:\u002F\u002Ffiorbio.com reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264].\u003C\u002Fp>\n\n\u003Cp>HCT\u002FPs that do not meet all the criteria set forth in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Your establishments do not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all the criteria in 21 CFR 1271.10(a). Therefore, your products are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>Specifically, an HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(2) if the HCT\u002FP is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” StemVive® and StemMaxx™ are not intended to perform the same basic function or functions of umbilical cord blood, umbilical cord, or amniotic membrane in the recipient as in the donor, such as forming and replenishing the lymphohematopoietic system (for cord blood); serving as a conduit (for umbilical cord); or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, using these products to treat orthopedic conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>In addition, your products fail to meet other criteria set forth in 21 CFR 1271.10(a). For example, StemVive®, StemMaxx™, and StemTru™ fail to meet 21 CFR 1271.10(a)(4). These cellular products, manufactured at least in part from donated umbilical cord blood, are dependent on the metabolic activity of living cells for their primary function and are not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use. In addition, StemVive®, StemMaxx™, and StemCellect™ fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord and\u002For amniotic membrane related to their utility for reconstruction, repair, or replacement.\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210, 211, and 1271.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, the FDA investigators issued a Form FDA 483 to you listing inspectional observations, which described a number of significant deviations from CGMP and CGTP applicable to your products. The deficiencies include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm failed to validate the aseptic processes used to manufacture over \u003Cstrong>(b)(4) \u003C\u002Fstrong>vials of your StemVive®, StemMaxx™; StemTru™ and StemCellect™ products (i.e., by performing media fill simulations) since your manufacturing operations began. By the nature of their routes of administration, your products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\n\n\u003Cp>b. Your employees use non-sterile personal protective equipment (PPE), for example lab coats, gloves and hair nets, during the manufacture of your products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to have separate or defined areas or such other control systems for your operations as are necessary to prevent contamination or mixups during the course of aseptic processing. [21 CFR 211.42(c)(10)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You allow two or more operators to process product within the same \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Processing by more than one technician in the same \u003Cstrong>(b)(4)\u003C\u002Fstrong> can significantly increase the potential for contamination.\u003C\u002Fp>\n\n\u003Cp>b. Your manufacturing facility is not classified with respect to air quality. The \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used to process your products, and operator gowning areas are located within an unclassified environment.\u003C\u002Fp>\n\n\u003Cp>c. Your firm has not established an adequate system for monitoring environmental conditions in the aseptic processing area where your products are manufactured.\u003C\u002Fp>\n\n\u003Cp>d. Your firm does not conduct personnel monitoring of operators working in the aseptic processing area where your products are manufactured.\u003C\u002Fp>\n\n\u003Cp>e. Your firm does not have a validated cleaning process for the aseptic processing area where your products are manufactured.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You have not established scientifically sound and appropriate specifications, standards, sampling plans and test procedures to assure that your products conform to appropriate standards of identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>b. You do not collect and test sterility samples that are representative of the lot size. You test \u003Cstrong>(b)(4)\u003C\u002Fstrong> for sterility and rely on the results of \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterility test to determine lot release despite the lot size, which may consist of as many as \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to include in laboratory records complete data derived from all tests necessary to assure compliance with established specifications and standards, including a statement of each method used in the testing of the sample that indicates the location of data that establish that the methods used in the testing of the sample meet proper standards of accuracy and reliability as applied to the product tested [21 CFR 211.194(a)(2)].\u003C\u002Fstrong> Specifically, lot release of your products is based on sterility testing; however, your in-house sterility test has not been validated. Accordingly, your laboratory records do not include a statement that indicates the location of data that establish that your sterility testing methods meet proper standards of accuracy and reliability as applied to your products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> Specifically, the manufacturing processes for your products have not been validated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish and follow written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, testing, and approval or rejection of components and drug product containers and closures [21 CFR 211.80(a)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. There are no written procedures describing in sufficient detail the criteria for approval or rejection of incoming human umbilical cord blood or human umbilical cord.\u003C\u002Fp>\n\n\u003Cp>b. There are no written procedures describing in sufficient detail the acceptance criteria for components used in manufacturing, including \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>micron and \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>micron filters, \u003Cstrong>(b)(4)\u003C\u002Fstrong> (glass) bottles, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and drug product containers and closures.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [21 CFR 211.67(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm failed to validate the cleaning process for your \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>b. There are no data or rationale for the cleaning agents used or their rotation for the cleaning of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> where manufacturing is performed.\u003C\u002Fp>\n\n\u003Cp>c. Your firm has not established written procedures for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filter and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> funnel that come into direct contact with your products during processing.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192].\u003C\u002Fstrong> Specifically, from July 2017 to January 2020, you failed to thoroughly investigate 16 sterility failures. The failed lots were discarded; however, there was no further evaluation to identify the contaminating microorganism, determine a root cause or determine if other product lots may have been affected by the failures.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine the appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> Specifically, you assign a two-to-six year expiration date to your products without supporting data.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10. Failure to establish and follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Although your firm received multiple complaints regarding your products, there was no supporting documentation to show that you performed an adequate follow-up and\u002For investigation of those complaints. We note that these complaints were categorized as adverse events on your complaint log.\u003C\u002Fp>\n\n\u003Cp>b. Written procedures describing the handling of all written and oral complaints do not include procedures for review of a complaint to determine whether the complaint represents a serious and\u002For unexpected adverse experience.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>11. Failure to prepare batch production and control records for each batch of drug product produced that include complete information relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your batch production record does not include documentation of the accomplishment of each significant step in the processing of your products as described in your work instructions. These work instructions include GLP-DOC-0008 entitled “Amniotic Membrane Injectable Product Isolation Processing Work Instruction”; GLP-DOC-0009, Revision 01 entitled “Cord Tissue and Blood Injectable Product Isolation Processing Work Instruction”; and GLP-DOC-010 entitled “Cord Tissue Flowable Product Isolation Processing Work Instruction.”\u003C\u002Fp>\n\n\u003Cp>b. The batch production record does not include documentation of the identity of each batch of component or in-process material used in the processing of your products.\u003C\u002Fp>\n\n\u003Cp>c. The batch production record does not consistently document the results of product sterility testing.\u003C\u002Fp>\n\n\u003Cp>d. The batch production record does not include a statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing (i.e., the quantity of vials produced in each product lot).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>12. Failure to establish, when appropriate, time limits for the completion of each phase of production to assure the quality of the drug product [21 CFR 211.111].\u003C\u002Fstrong> Specifically, your firm stores \u003Cstrong>(b)(4)\u003C\u002Fstrong> product (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> ml glass container in a commercial refrigerator in your unclassified lab area for up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to aliquoting the \u003Cstrong>(b)(4)\u003C\u002Fstrong> into a \u003Cstrong>(b)(4)\u003C\u002Fstrong> ml or \u003Cstrong>(b)(4)\u003C\u002Fstrong> ml final container. Your firm failed to validate the time limit the \u003Cstrong>(b)(4)\u003C\u002Fstrong> can be stored in such a manner without negatively impacting the final product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>13. Failure to routinely calibrate, inspect or check automatic, mechanical or electronic equipment or other types of equipment, including computers, or related systems that will perform a function satisfactorily, that are used in the manufacture, processing, packing and holding of a drug product, according to a written program designed to assure proper performance [21 CFR 211.68(a)].\u003C\u002Fstrong> Specifically, you failed to validate the software used to maintain your sterility testing results according to a written program designed to assure the software’s proper performance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>14. Failure to assign and label each HCT\u002FP that you manufacture with a distinct identification code in accordance with the requirements in 21 CFR 1271.290(c).\u003C\u002Fstrong> Specifically, you do not ensure that each HCT\u002FP that you manufacture is assigned and labeled with a distinct identification code that relates the HCT\u002FP to the donor and to all records pertaining to the HCT\u002FP and that labeling includes information designed to facilitate effective tracking, using the distinct identification code, from the donor to the recipient and from the recipient to the donor.\u003C\u002Fp>\n\n\u003Cp>FDA received your written responses, dated March 5 and April 16, 2021, to the inspectional observations on the Form FDA 483 issued at the conclusion of the inspection, and we have reviewed the contents. FDA acknowledges your commitment to voluntarily cease the manufacture and processing of new HCT\u002FPs until your third-party consultant has reviewed and audited your firm’s processes and procedures. We also acknowledge your commitment to not distribute HCT\u002FPs that remain in inventory until they have been resampled and retested for contamination. These commitments, along with the corrective actions described in the rest of your response, are not adequate to address the above-noted violations.\u003C\u002Fp>\n\n\u003Cp>Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA 483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facilities. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements for biological products, contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf at (313) 393-2034 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nKarlton Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations - Division 2\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> This letter does not pertain to HCT\u002FPs intended for autologous use or allogeneic use in a first-degree or second-degree blood relative. Accordingly, references in this letter to “HCT\u002FPs” or “your products” do not include products you manufacture that are intended for autologous use or allogeneic use in a first-degree or second-degree blood relative. FDA issued a separate Warning Letter to you, dated May 11, 2021, that pertains to those HCT\u002FPs.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nEliott D. Spencer, PhD\n\nRecipient Title\n\nOwner\u002FPresident\n\nUtah Cord Bank LLC dba Utah Cell Bank\n\n8675 S. Sandy Parkway, Suite 110\n\nSandy, UT 84070-6418\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations - Division 2\n\nUnited States\n\nWARNING LETTER\n\nAugust 10, 2021\n\nWarning Letter #OBPO 21-614013\n\nDear Dr. Spencer:\n\nDuring an inspection of your firms, Utah Cord Bank LLC (Utah Cord Bank), dba Utah Cell Bank, and FIOR Bioscience LLC (FIOR Bioscience), co-located at 8675 S. Sandy Parkway, Suite 110, Sandy, UT 84070, conducted between February 1 and February 11, 2021, United States Food and Drug Administration (FDA) investigators documented that you manufacture cellular products for allogeneic use, including: human umbilical cord blood, umbilical cord, and amniotic membrane derived cellular products with the brand names StemVive® and StemMaxx™ (also known as Stemii and Stemshot); a human umbilical cord blood derived product with the brand name StemTru™; and a human umbilical cord derived product with the brand name StemCellect™ (collectively, “your products”).1 FIOR Bioscience distributes your products directly to health care professionals and medical facilities. These products are intended for injection and are purported to be sterile.\n\nInformation and records gathered prior to and at the time of the inspection, including information on the FIOR Bioscience website, https:\u002F\u002Ffiorbio.com reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nYour products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264].\n\nHCT\u002FPs that do not meet all the criteria set forth in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nYour establishments do not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all the criteria in 21 CFR 1271.10(a). Therefore, your products are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\n\nSpecifically, an HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(2) if the HCT\u002FP is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” StemVive® and StemMaxx™ are not intended to perform the same basic function or functions of umbilical cord blood, umbilical cord, or amniotic membrane in the recipient as in the donor, such as forming and replenishing the lymphohematopoietic system (for cord blood); serving as a conduit (for umbilical cord); or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, using these products to treat orthopedic conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c).\n\nIn addition, your products fail to meet other criteria set forth in 21 CFR 1271.10(a). For example, StemVive®, StemMaxx™, and StemTru™ fail to meet 21 CFR 1271.10(a)(4). These cellular products, manufactured at least in part from donated umbilical cord blood, are dependent on the metabolic activity of living cells for their primary function and are not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use. In addition, StemVive®, StemMaxx™, and StemCellect™ fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord and\u002For amniotic membrane related to their utility for reconstruction, repair, or replacement.\n\nPlease be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210, 211, and 1271.\n\nAt the close of the inspection, the FDA investigators issued a Form FDA 483 to you listing inspectional observations, which described a number of significant deviations from CGMP and CGTP applicable to your products. The deficiencies include, but are not limited to, the following:\n\n1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. For example:\n\na. Your firm failed to validate the aseptic processes used to manufacture over (b)(4) vials of your StemVive®, StemMaxx™; StemTru™ and StemCellect™ products (i.e., by performing media fill simulations) since your manufacturing operations began. By the nature of their routes of administration, your products purport to be sterile and are expected to be sterile.\n\nb. Your employees use non-sterile personal protective equipment (PPE), for example lab coats, gloves and hair nets, during the manufacture of your products.\n\n2. Failure to have separate or defined areas or such other control systems for your operations as are necessary to prevent contamination or mixups during the course of aseptic processing. [21 CFR 211.42(c)(10)]. For example:\n\na. You allow two or more operators to process product within the same (b)(4). Processing by more than one technician in the same (b)(4) can significantly increase the potential for contamination.\n\nb. Your manufacturing facility is not classified with respect to air quality. The (b)(4), used to process your products, and operator gowning areas are located within an unclassified environment.\n\nc. Your firm has not established an adequate system for monitoring environmental conditions in the aseptic processing area where your products are manufactured.\n\nd. Your firm does not conduct personnel monitoring of operators working in the aseptic processing area where your products are manufactured.\n\ne. Your firm does not have a validated cleaning process for the aseptic processing area where your products are manufactured.\n\n3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example:\n\na. You have not established scientifically sound and appropriate specifications, standards, sampling plans and test procedures to assure that your products conform to appropriate standards of identity, strength, quality, and purity.\n\nb. You do not collect and test sterility samples that are representative of the lot size. You test (b)(4) for sterility and rely on the results of (b)(4) sterility test to determine lot release despite the lot size, which may consist of as many as (b)(4) vials.\n\n4. Failure to include in laboratory records complete data derived from all tests necessary to assure compliance with established specifications and standards, including a statement of each method used in the testing of the sample that indicates the location of data that establish that the methods used in the testing of the sample meet proper standards of accuracy and reliability as applied to the product tested [21 CFR 211.194(a)(2)]. Specifically, lot release of your products is based on sterility testing; however, your in-house sterility test has not been validated. Accordingly, your laboratory records do not include a statement that indicates the location of data that establish that your sterility testing methods meet proper standards of accuracy and reliability as applied to your products.\n\n5. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. Specifically, the manufacturing processes for your products have not been validated.\n\n6. Failure to establish and follow written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, testing, and approval or rejection of components and drug product containers and closures [21 CFR 211.80(a)]. For example:\n\na. There are no written procedures describing in sufficient detail the criteria for approval or rejection of incoming human umbilical cord blood or human umbilical cord.\n\nb. There are no written procedures describing in sufficient detail the acceptance criteria for components used in manufacturing, including (b)(4) micron and (b)(4) micron filters, (b)(4) (glass) bottles, and (b)(4), and drug product containers and closures.\n\n7. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [21 CFR 211.67(b)]. For example:\n\na. Your firm failed to validate the cleaning process for your (b)(4).\n\nb. There are no data or rationale for the cleaning agents used or their rotation for the cleaning of the (b)(4) where manufacturing is performed.\n\nc. Your firm has not established written procedures for the (b)(4) sterilization of the (b)(4) filter and the (b)(4) funnel that come into direct contact with your products during processing.\n\n8. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192]. Specifically, from July 2017 to January 2020, you failed to thoroughly investigate 16 sterility failures. The failed lots were discarded; however, there was no further evaluation to identify the contaminating microorganism, determine a root cause or determine if other product lots may have been affected by the failures.\n\n9. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine the appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, you assign a two-to-six year expiration date to your products without supporting data.\n\n10. Failure to establish and follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)]. For example:\n\na. Although your firm received multiple complaints regarding your products, there was no supporting documentation to show that you performed an adequate follow-up and\u002For investigation of those complaints. We note that these complaints were categorized as adverse events on your complaint log.\n\nb. Written procedures describing the handling of all written and oral complaints do not include procedures for review of a complaint to determine whether the complaint represents a serious and\u002For unexpected adverse experience.\n\n11. Failure to prepare batch production and control records for each batch of drug product produced that include complete information relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)]. For example:\n\na. Your batch production record does not include documentation of the accomplishment of each significant step in the processing of your products as described in your work instructions. These work instructions include GLP-DOC-0008 entitled “Amniotic Membrane Injectable Product Isolation Processing Work Instruction”; GLP-DOC-0009, Revision 01 entitled “Cord Tissue and Blood Injectable Product Isolation Processing Work Instruction”; and GLP-DOC-010 entitled “Cord Tissue Flowable Product Isolation Processing Work Instruction.”\n\nb. The batch production record does not include documentation of the identity of each batch of component or in-process material used in the processing of your products.\n\nc. The batch production record does not consistently document the results of product sterility testing.\n\nd. The batch production record does not include a statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing (i.e., the quantity of vials produced in each product lot).\n\n12. Failure to establish, when appropriate, time limits for the completion of each phase of production to assure the quality of the drug product [21 CFR 211.111]. Specifically, your firm stores (b)(4) product ((b)(4)) in a (b)(4) ml glass container in a commercial refrigerator in your unclassified lab area for up to (b)(4) prior to aliquoting the (b)(4) into a (b)(4) ml or (b)(4) ml final container. Your firm failed to validate the time limit the (b)(4) can be stored in such a manner without negatively impacting the final product.\n\n13. Failure to routinely calibrate, inspect or check automatic, mechanical or electronic equipment or other types of equipment, including computers, or related systems that will perform a function satisfactorily, that are used in the manufacture, processing, packing and holding of a drug product, according to a written program designed to assure proper performance [21 CFR 211.68(a)]. Specifically, you failed to validate the software used to maintain your sterility testing results according to a written program designed to assure the software’s proper performance.\n\n14. Failure to assign and label each HCT\u002FP that you manufacture with a distinct identification code in accordance with the requirements in 21 CFR 1271.290(c). Specifically, you do not ensure that each HCT\u002FP that you manufacture is assigned and labeled with a distinct identification code that relates the HCT\u002FP to the donor and to all records pertaining to the HCT\u002FP and that labeling includes information designed to facilitate effective tracking, using the distinct identification code, from the donor to the recipient and from the recipient to the donor.\n\nFDA received your written responses, dated March 5 and April 16, 2021, to the inspectional observations on the Form FDA 483 issued at the conclusion of the inspection, and we have reviewed the contents. FDA acknowledges your commitment to voluntarily cease the manufacture and processing of new HCT\u002FPs until your third-party consultant has reviewed and audited your firm’s processes and procedures. We also acknowledge your commitment to not distribute HCT\u002FPs that remain in inventory until they have been resampled and retested for contamination. These commitments, along with the corrective actions described in the rest of your response, are not adequate to address the above-noted violations.\n\nYour response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nNeither this letter nor the observations noted on the Form FDA 483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facilities. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements for biological products, contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf at (313) 393-2034 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations - Division 2\n\n______________________________\n\n1 This letter does not pertain to HCT\u002FPs intended for autologous use or allogeneic use in a first-degree or second-degree blood relative. Accordingly, references in this letter to “HCT\u002FPs” or “your products” do not include products you manufacture that are intended for autologous use or allogeneic use in a first-degree or second-degree blood relative. FDA issued a separate Warning Letter to you, dated May 11, 2021, that pertains to those HCT\u002FPs.","Utah Cord Bank LLC dba Utah Cell Bank","utah-cord-bank-llc-dba-utah-cell-bank-614013-08102021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Futah-cord-bank-llc-dba-utah-cell-bank-614013-08102021","2026-10-26T08:10:18.765289+00:00","2021-08-17","614013","Eliott D. Spencer, PhD","2026-08-20T02:41:41.014+00:00","2021-08-10",{"id":155,"raw":156,"subject":40,"body_html":160,"body_text":161,"firm_name":162,"letter_id":163,"created_at":67,"fei_number":19,"letter_url":164,"updated_at":165,"action_type":22,"case_status":23,"posted_date":166,"marcs_cms_no":167,"product_type":50,"closeout_date":19,"issuing_office":38,"recipient_name":168,"body_fetched_at":169,"delivery_method":53,"recipient_title":19,"reference_number":19,"action_taken_date":170,"medical_device_id":19,"response_letter_date":19},3433,[157,158,159,38,40,13,13,13],"\u003Ctime datetime=\"2021-03-30T13:20:00Z\">03\u002F30\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-26T04:00:00Z\">03\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmorin-enterprises-inc-dba-ecig-crib-614011-03262021\">Morin Enterprises Inc. d\u002Fb\u002Fa Ecig Crib \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kevin Morin, Debra Morin, and Amy Harris\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Morin Enterprises Inc. d\u002Fb\u002Fa Ecig Crib \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3027 Coon Rapids Blvd. NW\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Coon Rapids\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55433\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ecigcribcsr@gmail.com\"> ecigcribcsr@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 26, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Kevin Morin, Debra Morin, and Amy Harris:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website http:\u002F\u002Fecigcrib.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website http:\u002F\u002Fecigcrib.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: E Cig Crib - Planet of the Grapes E Liquid and E Cig Crib - Cotton Candy E Liquid.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 4,700 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2101556, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products c\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at \u003Cspan>(301) 796-9235\u003Ca>\u003C\u002Fa>\u003C\u002Fspan> or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Morin Enterprises Inc.\u003Cbr>\nAttn: Kevin Morin\u003Cbr>\n230 Dewey Str\u003Cbr>\nMankato, MN 56001\u003C\u002Fp>\n\n\u003Cp>Morin Enterprises Inc.\u003Cbr>\nAttn: Kevin Morin\u003Cbr>\n52112 190th Lane\u003Cbr>\nLake Crystal, MN 56055\u003C\u002Fp>\n\n\u003Cp>Morin Enterprises Inc. d\u002Fb\u002Fa E-Cig Crib\u003Cbr>\nAttn: \u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Google LLC\u003Cbr>\ngoogle-cloud-compliance@google.com\u003C\u002Fp>\n\n\u003Cp>Register.com, Inc.\u003Cbr>\nabuse@web.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nKevin Morin, Debra Morin, and Amy Harris\n\nMorin Enterprises Inc. d\u002Fb\u002Fa Ecig Crib\n\n3027 Coon Rapids Blvd. NW\n\nCoon Rapids, MN 55433\n\nUnited States\n\necigcribcsr@gmail.com\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMarch 26, 2021\n\nWARNING LETTER\n\nDear Kevin Morin, Debra Morin, and Amy Harris:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website http:\u002F\u002Fecigcrib.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website http:\u002F\u002Fecigcrib.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: E Cig Crib - Planet of the Grapes E Liquid and E Cig Crib - Cotton Candy E Liquid.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 4,700 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101556, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products c\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nMorin Enterprises Inc.\n\nAttn: Kevin Morin\n\n230 Dewey Str\n\nMankato, MN 56001\n\nMorin Enterprises Inc.\n\nAttn: Kevin Morin\n\n52112 190th Lane\n\nLake Crystal, MN 56055\n\nMorin Enterprises Inc. d\u002Fb\u002Fa E-Cig Crib\n\nAttn: (b)(6)\n\nGoogle LLC\n\ngoogle-cloud-compliance@google.com\n\nRegister.com, Inc.\n\nabuse@web.com","Morin Enterprises Inc. d\u002Fb\u002Fa Ecig Crib","morin-enterprises-inc-dba-ecig-crib-614011-03262021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmorin-enterprises-inc-dba-ecig-crib-614011-03262021","2026-10-26T08:09:27.968041+00:00","2021-03-30","614011","Kevin Morin, Debra Morin, and Amy Harris","2026-08-20T03:15:05.918+00:00","2021-03-26",{"id":172,"raw":173,"subject":178,"body_html":179,"body_text":180,"firm_name":181,"letter_id":182,"created_at":183,"fei_number":19,"letter_url":184,"updated_at":185,"action_type":22,"case_status":23,"posted_date":186,"marcs_cms_no":187,"product_type":130,"closeout_date":19,"issuing_office":177,"recipient_name":188,"body_fetched_at":189,"delivery_method":190,"recipient_title":19,"reference_number":191,"action_taken_date":192,"medical_device_id":19,"response_letter_date":19},1343,[174,175,176,177,178,13,13,13],"\u003Ctime datetime=\"2024-07-30T04:00:00Z\">07\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-24T04:00:00Z\">07\u002F24\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcorporacion-avicola-morovis-inc-681668-07242024\">Corporacion Avicola Morovis Inc\u003C\u002Fa>","Office of Regulatory Affairs","PHS Act\u002FShell Egg Regulation\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>24-HAFE4-WL-03\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Juan De La Vega\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Corporacion Avicola Morovis Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>PR-634 Km 2.2\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Barrio Franquez\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Morovis\u003C\u002Fspan> \u003Cspan>00687\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Puerto Rico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@corpavicola.com\"> info@corpavicola.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Regulatory Affairs\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>7\u002F24\u002F24\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>24-HAFE4-WL-03 \u002F CMS No. 681688\u003C\u002Fp>\u003Cp>Dear Mr. De La Vega:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your shell egg farm and egg processing facility, where your shell eggs are washed, graded and packed, located at Road 634 Km 2.2, Morovis, Puerto Rico. During our inspection of your farm from January 11, 2024, through March 14, 2024, FDA investigators found serious violations of the Prevention of Salmonella Enteritidis (SE) in Shell Eggs During Production, Storage, and Transportation regulation (the shell egg regulation), Title 21, Code of Federal Regulations, Part 118 (21 CFR Part 118). Failure to comply with the provisions of 21 CFR Part 118 causes your shell eggs to be in violation of section 361(a) of the Public Health Service Act (the PHS Act), 42 U.S.C. § 264(a). In addition, these violations render your shell eggs adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4), in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. You may find the Act, the PHS Act, and the shell egg regulation through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations. We received your farm’s response letter dated March 22, 2024, to the FDA-483. In the letter, you stated that you hired a consultant to assist in evaluating your operations and that you plan to submit an action plan to FDA within 30 calendar days. We received your secondary response on May 16, 2024, and are issuing this letter to advise you of FDA’s continued concerns and to also provide detailed information describing the findings at your farm.\u003C\u002Fp>\u003Cp>Your significant violations are as follows:\u003C\u002Fp>\u003Cp>1. You did not have and implement a written Salmonella Enteritidis prevention plan (SE Prevention Plan) that includes, at minimum, the SE prevention measures required by 21 CFR 118.4.\u003C\u002Fp>\u003Cp>a. \u003Cu>Biosecurity\u003C\u002Fu>\u003C\u002Fp>\u003Cp>You did not take steps to ensure that there is no introduction or transfer of SE into or among poultry houses, as required by 21 CFR 118.4(b). Specifically, your biosecurity program within your SE Prevention Plan dated May 2, 2023, addressed corrective actions in response to finding birds or other animals, but did not address measures for preventing wild birds, stray poultry, cats, and other animals from entering poultry houses, as required by 21 CFR 118.4(b)(4). On January 11, 2024, our investigators observed one wild bird flying across the laying hens’ cages on the top floor of poultry house \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, excrement from unidentified stray animals was observed on a walkway at the top floor of poultry house \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In response, farm employees removed the wild bird and conducted a visual inspection assessing for entry gaps and potential droppings. Your farm also requested an employee to clean\u002Fdisinfect the floor of poultry houses \u003Cstrong>(b)(4)\u003C\u002Fstrong> with a broom and spray a quaternary solution. However, these corrective actions alone are not adequate to prevent additional wild birds or other animals from entering your poultry houses. Additionally, although your farm completed installation of double wire and vinyl mesh around each poultry house in 2023, it was not sufficient to prevent ingress areas for external animals within your poultry houses.\u003C\u002Fp>\u003Cp>Your written response dated May 16, 2024, indicated that daily inspections inside and outside each poultry house will occur, which includes checking for breaks or openings larger than “1’ x ½’” and entry points for external animals. These daily inspections are reflected in your updated biosecurity program dated May 13, 2024. Despite these updates, we are concerned that the size of the openings may continue to present an ingress point to your poultry houses, given that some openings equal to or smaller than “1’ x ½’” may still provide an ingress opportunity to certain external animals.\u003C\u002Fp>\u003Cp>b. \u003Cu>Rodents, Flies, and other Pest Control\u003C\u002Fu>\u003C\u002Fp>\u003Cp>1. You did not monitor for the presence of rodents by appropriate methods, and when monitoring indicated unacceptable rodent activity within a poultry house, use appropriate methods to achieve satisfactory rodent control, as required by 21 CFR 118.4(c)(1). Specifically, your rodent control program within your SE Prevention Plan dated May 2, 2023, did not establish a threshold for acceptable or unacceptable activity for bait consumption for \u003Cstrong>(b)(4)\u003C\u002Fstrong> stations located on the lower part of each of your poultry houses. Further, you did not identify corrective actions if unacceptable activity was observed. Your plan stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The consumption of bait blocks was documented by your pest control contractor on several service reports, but no corrective actions were documented or implemented to address the presence of rodents. For example, for house \u003Cstrong>(b)(4)\u003C\u002Fstrong> there was evidence of bait consumption of \u003Cstrong>(b)(4)\u003C\u002Fstrong> blocks documented on May 29, 2023, July 24, 2023, August 31, 2023, October 9, 2023, December 29, 2023, and January 15, 2024. Additionally, on January 11, 2024, our investigators observed what appeared to be rodent fecal pellets on the premises of house \u003Cstrong>(b)(4)\u003C\u002Fstrong> in between the rodent stations \u003Cstrong>(b)(4)\u003C\u002Fstrong> but this data was not documented on your daily visual inspection logbook, as required by your SE Prevention Plan.\u003C\u002Fp>\u003Cp>In your response dated May 16, 2024, you provided an updated plan and indicated that you have \u003Cstrong>(b)(4)\u003C\u002Fstrong> internal rodent traps per poultry house and that by using the results of the daily inspections, you will determine the type of infestation on a weekly basis through a calculation. However, your rodent index calculation (i.e., the number of rodents divided by the bait quantities, multiplied by the bait quantities divided by seven) for determining the level of infestation does not appear to have a scientific basis. Specifically, the \"bait quantities\" on the denominator and numerator cancel each other out so the formula represents the number of rodents divided by seven. Further, your plan does not clearly identify a threshold when corrective actions should be taken, and instead merely states that “[c]orrective actions will be defined according to the type of disinfection obtained.”\u003C\u002Fp>\u003Cp>2. You did not implement your fly monitoring procedure and did not take appropriate corrective actions when monitoring indicated unacceptable activity, as required by 21 CFR 118.4(c)(2). Specifically, you did not take appropriate actions in regard to the presence of small flies on the sticky tapes. Your SE Prevention Plan dated May 2, 2023, stated \u003Cstrong>(b)(4)\u003C\u002Fstrong> sticky tapes were placed per house and tapes were counted \u003Cstrong>(b)(4)\u003C\u002Fstrong> per week. Your plan further stated if \u003Cstrong>(b)(4)\u003C\u002Fstrong> or more flies were observed, the affected areas will be fumigated, if necessary. During the inspection small flies, too numerous to count, were observed on one sticky tape located at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of house \u003Cstrong>(b)(4)\u003C\u002Fstrong>, one sticky tape located at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> near Column #\u003Cstrong>(b)(4)\u003C\u002Fstrong> of house \u003Cstrong>(b)(4)\u003C\u002Fstrong>, on two sticky tapes located at the back of house \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and two sticky tapes located in the walkway between \u003Cstrong>(b)(4)\u003C\u002Fstrong> of house \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The presence of these flies exceeded your \u003Cstrong>(b)(4)\u003C\u002Fstrong>-count threshold. However, no corrective action had been taken. Further, during the current inspection it was your practice to apply Permethrin \u003Cstrong>(b)(4)\u003C\u002Fstrong>% in and around the houses on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis as a control measure, regardless of the number of flies found on the sticky tapes. However, the pesticide label indicated that the product should not be used more than once every two weeks on areas where food, feed, and water are present.\u003C\u002Fp>\u003Cp>In your response dated May 16, 2024, you provided an updated SE Prevention Plan that calls for \u003Cstrong>(b)(4)\u003C\u002Fstrong>-gallon fly trap bags per poultry house. You indicate that \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, this corrective action alone is not an appropriate method to achieve satisfactory fly control, as you are not taking sufficient corrective actions within the poultry houses to control the presence of flies. Further, your plan does not detail the frequency of your monitoring and does not indicate whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong> flies is per bag or per house.\u003C\u002Fp>\u003Cp>3. You did not remove debris within poultry houses and vegetation and debris outside your poultry houses that may provide harborage for pests, as required by 21 CFR 118.4(c)(3). Specifically, our investigators observed spilled chicken feed around rodent traps and walkways on the second floor inside the poultry houses \u003Cstrong>(b)(4)\u003C\u002Fstrong>; at least three wild birds feeding from spilled feed and broken eggs below the conveyor belt connecting poultry houses \u003Cstrong>(b)(4)\u003C\u002Fstrong>; multiple bones of an unidentified animal on the grass next to poultry house \u003Cstrong>(b)(4)\u003C\u002Fstrong>; liquid manure with puddles of stagnant water in the manure pits of all poultry houses; and overgrown vegetation around the premises of poultry house \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your SE Prevention Plan dated May 2, 2023, stated that all areas around the houses will be inspected to ensure that there is no accumulation of debris, overgrown vegetation, leaks of organic matter, puddles of water, spilled chicken feed, and broken eggs, and describes the corrective actions to be implemented if these conditions are observed. However, you did not follow your established control measures nor implement corrective actions.\u003C\u002Fp>\u003Cp>In your response dated May 16, 2024, you stated that the high vegetation adjacent to the poultry house was removed; feed spill will be cleaned after each feeding cycle; leaks in pipes, hoses, and other water sources were fixed; feeding equipment and conveyors will be inspected daily to identify potential spillage; and you hired new staff for daily inspections to ensure feed spills and cracked eggs are cleaned daily. FDA has previously communicated concerns with harborage in and around your poultry houses. Your corrective actions will be verified during the following inspection.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of the violations that may exist at your farm or in connection with your shell eggs. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your shell egg production practices are conducted in compliance with federal law, including the FD&amp;C Act, the PHS Act, and FDA’s egg safety rule.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or the initiation of administrative enforcement procedures under 21 CFR 118.12(a).\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that you have complied with pertinent laws and regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written response should be directed to the Food and Drug Administration, attention to: Mr. Ramon Hernández, Program Division Director, HAFE4, 466 Fernández Juncos Avenue, San Juan, Puerto Rico 00901-3223. If you have any questions regarding this letter, please contact Ms. Marilyn Santiago, Compliance Officer, at (787) 729-8707 or via email at Marilyn.santiago@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Ramon A. Hernández&nbsp;&nbsp;\u003Cbr>Program Division Director\u003Cbr>Office of Human and Animal Food Operations-&nbsp;&nbsp;\u003Cbr>East IV Division\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n24-HAFE4-WL-03\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Juan De La Vega\n\nRecipient Title\n\nPresident\n\nCorporacion Avicola Morovis Inc\n\nPR-634 Km 2.2\n\nBarrio Franquez\n\nMorovis 00687\n\nPuerto Rico\n\ninfo@corpavicola.com\n\nIssuing Office:\n\nOffice of Regulatory Affairs\n\nUnited States\n\n7\u002F24\u002F24\nWARNING LETTER\n24-HAFE4-WL-03 \u002F CMS No. 681688\nDear Mr. De La Vega:\nThe United States Food and Drug Administration (FDA) inspected your shell egg farm and egg processing facility, where your shell eggs are washed, graded and packed, located at Road 634 Km 2.2, Morovis, Puerto Rico. During our inspection of your farm from January 11, 2024, through March 14, 2024, FDA investigators found serious violations of the Prevention of Salmonella Enteritidis (SE) in Shell Eggs During Production, Storage, and Transportation regulation (the shell egg regulation), Title 21, Code of Federal Regulations, Part 118 (21 CFR Part 118). Failure to comply with the provisions of 21 CFR Part 118 causes your shell eggs to be in violation of section 361(a) of the Public Health Service Act (the PHS Act), 42 U.S.C. § 264(a). In addition, these violations render your shell eggs adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4), in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. You may find the Act, the PHS Act, and the shell egg regulation through links on FDA’s home page at www.fda.gov.\nAt the conclusion of the inspection, FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations. We received your farm’s response letter dated March 22, 2024, to the FDA-483. In the letter, you stated that you hired a consultant to assist in evaluating your operations and that you plan to submit an action plan to FDA within 30 calendar days. We received your secondary response on May 16, 2024, and are issuing this letter to advise you of FDA’s continued concerns and to also provide detailed information describing the findings at your farm.\nYour significant violations are as follows:\n1. You did not have and implement a written Salmonella Enteritidis prevention plan (SE Prevention Plan) that includes, at minimum, the SE prevention measures required by 21 CFR 118.4.\na. Biosecurity\nYou did not take steps to ensure that there is no introduction or transfer of SE into or among poultry houses, as required by 21 CFR 118.4(b). Specifically, your biosecurity program within your SE Prevention Plan dated May 2, 2023, addressed corrective actions in response to finding birds or other animals, but did not address measures for preventing wild birds, stray poultry, cats, and other animals from entering poultry houses, as required by 21 CFR 118.4(b)(4). On January 11, 2024, our investigators observed one wild bird flying across the laying hens’ cages on the top floor of poultry house (b)(4). In addition, excrement from unidentified stray animals was observed on a walkway at the top floor of poultry house (b)(4).\nIn response, farm employees removed the wild bird and conducted a visual inspection assessing for entry gaps and potential droppings. Your farm also requested an employee to clean\u002Fdisinfect the floor of poultry houses (b)(4) with a broom and spray a quaternary solution. However, these corrective actions alone are not adequate to prevent additional wild birds or other animals from entering your poultry houses. Additionally, although your farm completed installation of double wire and vinyl mesh around each poultry house in 2023, it was not sufficient to prevent ingress areas for external animals within your poultry houses.\nYour written response dated May 16, 2024, indicated that daily inspections inside and outside each poultry house will occur, which includes checking for breaks or openings larger than “1’ x ½’” and entry points for external animals. These daily inspections are reflected in your updated biosecurity program dated May 13, 2024. Despite these updates, we are concerned that the size of the openings may continue to present an ingress point to your poultry houses, given that some openings equal to or smaller than “1’ x ½’” may still provide an ingress opportunity to certain external animals.\nb. Rodents, Flies, and other Pest Control\n1. You did not monitor for the presence of rodents by appropriate methods, and when monitoring indicated unacceptable rodent activity within a poultry house, use appropriate methods to achieve satisfactory rodent control, as required by 21 CFR 118.4(c)(1). Specifically, your rodent control program within your SE Prevention Plan dated May 2, 2023, did not establish a threshold for acceptable or unacceptable activity for bait consumption for (b)(4) stations located on the lower part of each of your poultry houses. Further, you did not identify corrective actions if unacceptable activity was observed. Your plan stated that (b)(4). The consumption of bait blocks was documented by your pest control contractor on several service reports, but no corrective actions were documented or implemented to address the presence of rodents. For example, for house (b)(4) there was evidence of bait consumption of (b)(4) blocks documented on May 29, 2023, July 24, 2023, August 31, 2023, October 9, 2023, December 29, 2023, and January 15, 2024. Additionally, on January 11, 2024, our investigators observed what appeared to be rodent fecal pellets on the premises of house (b)(4) in between the rodent stations (b)(4) but this data was not documented on your daily visual inspection logbook, as required by your SE Prevention Plan.\nIn your response dated May 16, 2024, you provided an updated plan and indicated that you have (b)(4) internal rodent traps per poultry house and that by using the results of the daily inspections, you will determine the type of infestation on a weekly basis through a calculation. However, your rodent index calculation (i.e., the number of rodents divided by the bait quantities, multiplied by the bait quantities divided by seven) for determining the level of infestation does not appear to have a scientific basis. Specifically, the \"bait quantities\" on the denominator and numerator cancel each other out so the formula represents the number of rodents divided by seven. Further, your plan does not clearly identify a threshold when corrective actions should be taken, and instead merely states that “[c]orrective actions will be defined according to the type of disinfection obtained.”\n2. You did not implement your fly monitoring procedure and did not take appropriate corrective actions when monitoring indicated unacceptable activity, as required by 21 CFR 118.4(c)(2). Specifically, you did not take appropriate actions in regard to the presence of small flies on the sticky tapes. Your SE Prevention Plan dated May 2, 2023, stated (b)(4) sticky tapes were placed per house and tapes were counted (b)(4) per week. Your plan further stated if (b)(4) or more flies were observed, the affected areas will be fumigated, if necessary. During the inspection small flies, too numerous to count, were observed on one sticky tape located at the (b)(4) of house (b)(4), one sticky tape located at the (b)(4) near Column #(b)(4) of house (b)(4), on two sticky tapes located at the back of house (b)(4), and two sticky tapes located in the walkway between (b)(4) of house (b)(4). The presence of these flies exceeded your (b)(4)-count threshold. However, no corrective action had been taken. Further, during the current inspection it was your practice to apply Permethrin (b)(4)% in and around the houses on a (b)(4) basis as a control measure, regardless of the number of flies found on the sticky tapes. However, the pesticide label indicated that the product should not be used more than once every two weeks on areas where food, feed, and water are present.\nIn your response dated May 16, 2024, you provided an updated SE Prevention Plan that calls for (b)(4)-gallon fly trap bags per poultry house. You indicate that (b)(4). However, this corrective action alone is not an appropriate method to achieve satisfactory fly control, as you are not taking sufficient corrective actions within the poultry houses to control the presence of flies. Further, your plan does not detail the frequency of your monitoring and does not indicate whether the (b)(4) flies is per bag or per house.\n3. You did not remove debris within poultry houses and vegetation and debris outside your poultry houses that may provide harborage for pests, as required by 21 CFR 118.4(c)(3). Specifically, our investigators observed spilled chicken feed around rodent traps and walkways on the second floor inside the poultry houses (b)(4); at least three wild birds feeding from spilled feed and broken eggs below the conveyor belt connecting poultry houses (b)(4); multiple bones of an unidentified animal on the grass next to poultry house (b)(4); liquid manure with puddles of stagnant water in the manure pits of all poultry houses; and overgrown vegetation around the premises of poultry house (b)(4). Your SE Prevention Plan dated May 2, 2023, stated that all areas around the houses will be inspected to ensure that there is no accumulation of debris, overgrown vegetation, leaks of organic matter, puddles of water, spilled chicken feed, and broken eggs, and describes the corrective actions to be implemented if these conditions are observed. However, you did not follow your established control measures nor implement corrective actions.\nIn your response dated May 16, 2024, you stated that the high vegetation adjacent to the poultry house was removed; feed spill will be cleaned after each feeding cycle; leaks in pipes, hoses, and other water sources were fixed; feeding equipment and conveyors will be inspected daily to identify potential spillage; and you hired new staff for daily inspections to ensure feed spills and cracked eggs are cleaned daily. FDA has previously communicated concerns with harborage in and around your poultry houses. Your corrective actions will be verified during the following inspection.\nThis letter is not intended to be an all-inclusive statement of the violations that may exist at your farm or in connection with your shell eggs. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your shell egg production practices are conducted in compliance with federal law, including the FD&C Act, the PHS Act, and FDA’s egg safety rule.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or the initiation of administrative enforcement procedures under 21 CFR 118.12(a).\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that you have complied with pertinent laws and regulations, include your reasoning and any supporting information for our consideration.\nYour written response should be directed to the Food and Drug Administration, attention to: Mr. Ramon Hernández, Program Division Director, HAFE4, 466 Fernández Juncos Avenue, San Juan, Puerto Rico 00901-3223. If you have any questions regarding this letter, please contact Ms. Marilyn Santiago, Compliance Officer, at (787) 729-8707 or via email at Marilyn.santiago@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nRamon A. Hernández\nProgram Division Director\nOffice of Human and Animal Food Operations-\nEast IV Division","Corporacion Avicola Morovis Inc","corporacion-avicola-morovis-inc-681668-07242024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcorporacion-avicola-morovis-inc-681668-07242024","2026-10-26T08:08:18.217603+00:00","2024-07-30","681668","Mr. Juan De La Vega","2026-08-19T23:55:23.278+00:00","VIA Electronic Mail","24-HAFE4-WL-03","2024-07-24",{"id":194,"raw":195,"subject":40,"body_html":199,"body_text":200,"firm_name":201,"letter_id":202,"created_at":18,"fei_number":19,"letter_url":203,"updated_at":204,"action_type":22,"case_status":23,"posted_date":205,"marcs_cms_no":206,"product_type":50,"closeout_date":19,"issuing_office":38,"recipient_name":19,"body_fetched_at":207,"delivery_method":19,"recipient_title":19,"reference_number":208,"action_taken_date":205,"medical_device_id":19,"response_letter_date":19},1524,[196,197,198,38,40,13,13,13],"\u003Ctime datetime=\"2024-04-12T19:00:00Z\">04\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-12T04:00:00Z\">04\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvape-dojo-corporate-headquarters-681680-04122024\">Vape Dojo Corporate Headquarters \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2401036\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Vape Dojo Corporate Headquarters \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>721 Hanover Pike, Suite 123\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hampstead\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>21074\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: FDA Warning Letter Regarding Tobacco Retailer Inspection Violation\u003Cbr>\nReference Number: ER2401036\u003C\u002Fp>\n\n\u003Cp>Dear Sir or Madam:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter is notification from the United States Food and Drug Administration (FDA) advising you that Vape Dojo was observed to be in violation of federal tobacco laws and regulations. \u003Cu>Failure to address this violation may result in FDA initiating regulatory or legal action, including monetary penalties\u003C\u002Fu>. Your response is requested in 15 working days.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On December 15, 2023, an inspector representing the FDA completed an inspection of the establishment located at 721 Hanover Pike, Suite 123, Hampstead, MD 21074. During this inspection, the establishment was in violation because your establishment offered for sale an electronic nicotine delivery system (ENDS) product that lacks the required marketing authorization.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that the establishment sells and\u002For distributes tobacco products, including ENDS products, which requires that the establishment and its owners comply with federal laws and regulations governing the sale, distribution, and\u002For advertising of such products. The violation observed during the December 15, 2023, inspection includes the following:\u003C\u002Fp>\n\n\u003Cp>1. The establishment offered for sale tobacco products that are required to have, but lack, premarket authorization. Specifically, on December 15, 2023, the establishment offered for sale a Vape Dojo Berry Smoothie 120 ML 0.6% e-liquid product.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (Section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under Section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under Section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (Section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under Section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under Section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>The ENDS product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under Section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under Section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under Section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by Section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\n\n\u003Cp>The listed violation causes the ENDS product you offer for sale or distribution in the United States to be \"adulterated\" and \"misbranded\" under Sections 902 and 903 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Under Section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), this product is a tobacco product because it is made or derived from tobacco or contains nicotine from any source, and is intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under Section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>On March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under 21 U.S.C. § 321(rr) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>As of April 14, 2022, it is illegal for a retailer to sell any tobacco product, containing nicotine from any source – including cigarettes, smokeless tobacco, cigars, and e-cigarettes – to anyone under 21.\u003Cbr>\n\u003Cbr>\nPlease be aware that the FD&amp;C Act requires “new tobacco products” to have premarket authorization. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007. See Section 910(a) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your establishment markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to address the violation listed above. Failure to address any violations of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may result in FDA initiating regulatory or legal action. These actions may include, but are not limited to, civil money penalty, no-tobacco-sale order, seizure, and\u002For injunction. However, this Warning Letter does not constitute \"written notice\" for purposes of Section 303(f)(9)(B)(i)(II) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please note that this warning letter does not constitute final agency action, but if you have evidence or information that you believe demonstrates that this notice was issued in error, you should preserve any evidence or information relevant to this warning letter in the event FDA initiates regulatory or legal action at a later date.\u003C\u002Fp>\n\n\u003Cp>Your establishment may have previously received a Warning Letter, Civil Monetary Penalty, or No-Tobacco-Sale Order from FDA. Although this Warning Letter includes violation(s) of Sections 902 and 903 of the FD&amp;C Act, please remember your ongoing obligation to comply with the regulations in 21 C.F.R. Part 1140.\u003C\u002Fp>\n\n\u003Cp>The violation indicated in this letter may not be a complete list of violations at the establishment.\u003C\u002Fp>\n\n\u003Cp>We will periodically inspect your establishment and review your promotional activities (e.g., website(s)) related to FDA-regulated tobacco products to assess your compliance with all applicable laws and regulations, including access, marketing, labeling, and advertising restrictions.\u003C\u002Fp>\n\n\u003Cp>For more information on these requirements, helpful resources for retailers, a database of inspections, and retailer education materials, visit our website at http:\u002F\u002Fwww.fda.gov\u002FTobaccoProducts. The following Guidance documents provide additional information on compliance with retailer responsibilities:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Guidance for Industry: Compliance with Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Protect Children and Adolescents\u003C\u002Fem> (https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fproducts-guidance-regulations\u002Frules-regulations-and-guidance)\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Small Entity Compliance Guide: FDA Deems Certain Tobacco Products Subject to FDA Authority, Sales and Distribution Restrictions, and Health Warning Requirements for Packages and Advertisements\u003C\u002Fem> (https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fproducts-guidance-regulations\u002Frules-regulations-and-guidance)\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization\u003C\u002Fem> (https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fproducts-guidance-regulations\u002Frules-regulations-and-guidance).\u003C\u002Fp>\n\n\u003Cp>You have 15 working days from the date you receive this letter to respond. In your written response, explain your plan for addressing the listed violation and preventing future violations. Include a telephone number and address. Note your reference number of ER2401036 in your response and mail it to:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Tobacco Products\u003Cbr>\nDocument Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions, contact the Center for Tobacco Products via email at CTP-WL@fda.hhs.gov or via phone at 1-877-CTP-1373. Have your reference number ready when you call and include it with any email communications.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Atencio\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Reference #:\n\nER2401036\n\nProduct:\n\nTobacco\n\nRecipient:\n\nVape Dojo Corporate Headquarters\n\n721 Hanover Pike, Suite 123\n\nHampstead, MD 21074\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nRe: FDA Warning Letter Regarding Tobacco Retailer Inspection Violation\n\nReference Number: ER2401036\n\nDear Sir or Madam:\n\nThis Warning Letter is notification from the United States Food and Drug Administration (FDA) advising you that Vape Dojo was observed to be in violation of federal tobacco laws and regulations. Failure to address this violation may result in FDA initiating regulatory or legal action, including monetary penalties. Your response is requested in 15 working days.\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOn December 15, 2023, an inspector representing the FDA completed an inspection of the establishment located at 721 Hanover Pike, Suite 123, Hampstead, MD 21074. During this inspection, the establishment was in violation because your establishment offered for sale an electronic nicotine delivery system (ENDS) product that lacks the required marketing authorization.\n\nThis inspection revealed that the establishment sells and\u002For distributes tobacco products, including ENDS products, which requires that the establishment and its owners comply with federal laws and regulations governing the sale, distribution, and\u002For advertising of such products. The violation observed during the December 15, 2023, inspection includes the following:\n\n1. The establishment offered for sale tobacco products that are required to have, but lack, premarket authorization. Specifically, on December 15, 2023, the establishment offered for sale a Vape Dojo Berry Smoothie 120 ML 0.6% e-liquid product.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (Section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under Section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under Section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (Section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under Section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under Section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nThe ENDS product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under Section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under Section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under Section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by Section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\n\nThe listed violation causes the ENDS product you offer for sale or distribution in the United States to be \"adulterated\" and \"misbranded\" under Sections 902 and 903 of the FD&C Act.\n\nUnder Section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), this product is a tobacco product because it is made or derived from tobacco or contains nicotine from any source, and is intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under Section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nOn March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under 21 U.S.C. § 321(rr) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nAs of April 14, 2022, it is illegal for a retailer to sell any tobacco product, containing nicotine from any source – including cigarettes, smokeless tobacco, cigars, and e-cigarettes – to anyone under 21.\n\nPlease be aware that the FD&C Act requires “new tobacco products” to have premarket authorization. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007. See Section 910(a) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has determined that your establishment markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nYou should take prompt action to address the violation listed above. Failure to address any violations of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may result in FDA initiating regulatory or legal action. These actions may include, but are not limited to, civil money penalty, no-tobacco-sale order, seizure, and\u002For injunction. However, this Warning Letter does not constitute \"written notice\" for purposes of Section 303(f)(9)(B)(i)(II) of the FD&C Act.\n\nPlease note that this warning letter does not constitute final agency action, but if you have evidence or information that you believe demonstrates that this notice was issued in error, you should preserve any evidence or information relevant to this warning letter in the event FDA initiates regulatory or legal action at a later date.\n\nYour establishment may have previously received a Warning Letter, Civil Monetary Penalty, or No-Tobacco-Sale Order from FDA. Although this Warning Letter includes violation(s) of Sections 902 and 903 of the FD&C Act, please remember your ongoing obligation to comply with the regulations in 21 C.F.R. Part 1140.\n\nThe violation indicated in this letter may not be a complete list of violations at the establishment.\n\nWe will periodically inspect your establishment and review your promotional activities (e.g., website(s)) related to FDA-regulated tobacco products to assess your compliance with all applicable laws and regulations, including access, marketing, labeling, and advertising restrictions.\n\nFor more information on these requirements, helpful resources for retailers, a database of inspections, and retailer education materials, visit our website at http:\u002F\u002Fwww.fda.gov\u002FTobaccoProducts. The following Guidance documents provide additional information on compliance with retailer responsibilities:\n\nGuidance for Industry: Compliance with Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Protect Children and Adolescents (https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fproducts-guidance-regulations\u002Frules-regulations-and-guidance)\n\nSmall Entity Compliance Guide: FDA Deems Certain Tobacco Products Subject to FDA Authority, Sales and Distribution Restrictions, and Health Warning Requirements for Packages and Advertisements (https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fproducts-guidance-regulations\u002Frules-regulations-and-guidance)\n\nEnforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization (https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fproducts-guidance-regulations\u002Frules-regulations-and-guidance).\n\nYou have 15 working days from the date you receive this letter to respond. In your written response, explain your plan for addressing the listed violation and preventing future violations. Include a telephone number and address. Note your reference number of ER2401036 in your response and mail it to:\n\nFood and Drug Administration\n\nCenter for Tobacco Products\n\nDocument Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions, contact the Center for Tobacco Products via email at CTP-WL@fda.hhs.gov or via phone at 1-877-CTP-1373. Have your reference number ready when you call and include it with any email communications.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Atencio\n\nActing Director\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Vape Dojo Corporate Headquarters","vape-dojo-corporate-headquarters-681680-04122024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvape-dojo-corporate-headquarters-681680-04122024","2026-10-26T08:10:19.768766+00:00","2024-04-12","681680","2026-08-20T00:11:08.992+00:00","ER2401036",{"id":210,"raw":211,"subject":216,"body_html":217,"body_text":218,"firm_name":219,"letter_id":220,"created_at":45,"fei_number":19,"letter_url":221,"updated_at":222,"action_type":22,"case_status":23,"posted_date":223,"marcs_cms_no":224,"product_type":130,"closeout_date":19,"issuing_office":215,"recipient_name":225,"body_fetched_at":226,"delivery_method":227,"recipient_title":19,"reference_number":19,"action_taken_date":228,"medical_device_id":19,"response_letter_date":19},2558,[212,213,214,215,216,13,13,13],"\u003Ctime datetime=\"2022-07-19T13:20:00Z\">07\u002F19\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-06-10T04:00:00Z\">06\u002F10\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fyoung-living-essential-oils-corporate-615777-06102022\">Young Living Essential Oils Corporate\u003C\u002Fa>","Office of Human and Animal Food Operations – West Division 4","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mary B. Young\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Co-Founder and Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Young Living Essential Oils Corporate\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3125 W Executive Pkwy\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lehi\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84043\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations – West Division 4\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 10, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>RE: 615777\u003C\u002Fp>\n\n\u003Cp>Dear Mrs. Young:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the Food and Drug Administration (FDA) reviewed your website and social media accounts (e.g., Instagram and Facebook) for several Young Living Consultants in May 2022 and has determined that your Young Living Consultants market many of your products, including, but not limited to, Frankincense Essential Oil, Lemon Essential Oil, Lavender Essential Oil, DiGize Essential Oil Blend, Thieves Essential Oil Blend (hereinafter \"Essential Oil\" products), Lemongrass Vitality, Peppermint Vitality (hereinafter \"Vitality\" products), Ningxia (hereinafter “Ningxia” product), Nature’s Ultra CBD Beauty Boost, Nature’s Ultra CBD Muscle Rub, Nature’s Ultra CBD Pep Bundle, Nature’s Ultra Calm CBD Roll-On, Nature’s Ultra Cinnamon CBD Oil, Nature’s Ultra Citrus CBD Oil, and Nature’s Ultra Cool Mint CBD Oil (hereinafter \"Nature's Ultra CBD\" products) and that you take orders for these products from your websites at the internet addresses www.youngliving.com and https:\u002F\u002Fnaturesultra.com.\u003C\u002Fp>\n\n\u003Cp>Additionally, we have also reviewed social media accounts of your Young Living Consultants at www.stillbeingmolly.com, www.instagram.com\u002Fawelllivedlife, www.instagram.com\u002Fpeace.love.essentials, www.instagram.com\u002Fthehollanderhome, www.instagram.com\u002Ftiffaney_ann, and www.facebook.com\u002Fessentialoilsaddict. You market your Young Living “Essential Oil”, “Vitality”, “Ningxia”, and “Nature’s Ultra CBD” products through these paid consultants. Your compensation plan for your consultants is explained on your website at https:\u002F\u002Fwww.youngliving.com\u002Fus\u002Fen\u002Fcompany\u002Fcompensation-plan. Consumers interested in your products are then redirected by your consultants to your websites www.youngliving.com and www.naturesultra.com to purchase your products and\u002For register as “members” (i.e., consultants).\u003C\u002Fp>\n\n\u003Cp>Your \"Essential Oil\", \"Vitality\", “Ningxia”, and \"Nature's Ultra CBD\" products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. The intended use of a product may be determined by, among other things, its labeling, advertising, and the circumstances surrounding its distribution [21 C.F.R. § 201.128]. As explained further below, these products are also unapproved new drugs and misbranded drugs. Introducing or delivering these products for introduction into interstate commerce violates the Act. You can find the Act through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of claims found on your websites, as well as your Young Living Consultants’ social media account postings, that provide evidence of the intended uses of your products (as defined by 21 CFR § 201.128) as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>\"Essential Oil\" products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the website www.stillbeingmolly.com (Molly Buckley Stillman, Consultant #1852080), under the Essential Oil category:\u003C\u002Fp>\n\n\u003Cp>• “20 Uses for Frankincense Essential Oil…”\u003Cbr>\n&nbsp; &nbsp; o “16. May ease symptoms of discomfort from a urinary tract infection”\u003Cbr>\n&nbsp; &nbsp; o “17. May ease symptoms of discomfort from a yeast infection”\u003Cbr>\n&nbsp; &nbsp; o “19. Great to use … for a homemade sunscreen”\u003C\u002Fp>\n\n\u003Cp>• “30 Uses for Lemon Essential Oil...”\u003Cbr>\n&nbsp; &nbsp; o “3…sometimes proves to be as effective as stone-breaking chanca piedra pills for the kidney stones.”\u003Cbr>\n&nbsp; &nbsp; o “19. Use (especially along with lavender and peppermint) to ease those seasonal sniffles and runny noses”\u003Cbr>\n&nbsp; &nbsp; o “23. Can be used to combat acne…”\u003Cbr>\n&nbsp; &nbsp; o “24. May ease symptoms from urinary tract infections”\u003Cbr>\n&nbsp; &nbsp; o “28. May reduce inflammation”\u003C\u002Fp>\n\n\u003Cp>• “35 Uses for Lavender Essential Oil…”\u003Cbr>\n&nbsp; &nbsp; o “9. Use in a vegetable capsule, a teaspoon of honey … to ease those seasonal sniffles (especially this time of year with ALL of the pollen)”\u003C\u002Fp>\n\n\u003Cp>On the social media account www.instagram.com\u002Fawelllivedlife (Carol Yeh-Garner, Consultant #1533467, Royal Crown Diamond Member)\u003C\u002Fp>\n\n\u003Cp>• May 24, 2020: “Phenolpropanoids… The Phenolpropanoids and phenols in essential oils… attack invading microbes and parasites…found in clove, peppermint [Vitality], fennel, basil and wintergreen.”\u003C\u002Fp>\n\n\u003Cp>• October 9, 2019: “…my friend…added me to a product education group where I learned that taking lemon [Essential Oil], lavender [Essential Oil] and peppermint [Vitality] could help with allergy symptoms like post-nasal drip, sneezing and itchy eyes…I used those oils to help with my allergies.”\u003C\u002Fp>\n\n\u003Cp>On the social media account www.instagram.com\u002Fpeace.love.essentials (Hannah Leiden-Olsen, Consultant #18682287, Executive Member)\u003C\u002Fp>\n\n\u003Cp>• March 5, 2021: Video Image of Frankincense Essential Oil “…can help with arthritis…asthma…”\u003C\u002Fp>\n\n\u003Cp>On the social media account www.instagram.com\u002Fthehollanderhome (Madison Hollander, Consultant #12438030)\u003C\u002Fp>\n\n\u003Cp>• March 9, 2020: “Digize [Essential Oil Blend]…heartburn”\u003C\u002Fp>\n\n\u003Cp>On the social media account, www.instagram.com\u002Ftiffaney_ann (Tiffaney Dwyer, Consultant #2472927)\u003C\u002Fp>\n\n\u003Cp>• February 8, 2021: Image of Lavender Essential Oil – “Lavender-…Helps allergies…”\u003C\u002Fp>\n\n\u003Cp>• October 2, 2019: Thieves – “…a head cold. Sneezing, watering eyes, running\u002Fstuffed nose…even body aches…Today- however, I’m still feeling a little tired, my ears don’t hurt anymore, and I feel MUCH BETTER. The remedy, thieves [Essential Oil Blend] under the tongue all day long and an overdose of YL Vitamin C…ready to beat the cold and flu season…DM ME!!!”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>\"Vitality\" products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the social media account www.instagram.com\u002Fthehollanderhome (Madison Hollander, Consultant #12438030)\u003C\u002Fp>\n\n\u003Cp>• July 28, 2020: Image of Lemongrass Vitality – “Lemongrass poses a very strong argument for being the ‘go-to’ when you find yourself not feeling well, battling inflammation, infection, stomach upset, stuffy sinuses…high body temps…high blood pressure, high cholesterol…If it’s stomach upset, bladder discomfort, cholesterol, or blood pressure that we are looking to improve, we ingest.”\u003C\u002Fp>\n\n\u003Cp>• March 9, 2020: “Peppermint [Vitality]…headache…”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>“Ningxia” product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the social media account www.instagram.com\u002Fthehollanderhome (Madison Hollander, Consultant #12438030)\u003Cbr>\n\u003Cbr>\n• December 1, 2020: Image of Ningxia – “Ningxia - scientifically proven to be the highest antioxidant food source in the world…Inflammation, disease, and cancer are all driven by Free Radicals…Antioxidants neutralize free radicals, meaning they stop them from doing damage… reduced inflammation, healthy cholesterol and blood sugar.”\u003C\u002Fp>\n\n\u003Cp>On the social media account www.instagram.com\u002Ftiffaney_ann (Tiffaney Dwyer, Consultant #2472927)\u003C\u002Fp>\n\n\u003Cp>• January 14, 2020: Ningxia – “…we’ve had Ningxia as part of our daily routine, we don’t get the flu, when we get a cold it’s not that bad at all and it’s short lived…”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>\"Nature's Ultra CBD\" products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your website www.youngliving.com\u003C\u002Fp>\n\n\u003Cp>• “CBD MUSCLE RUB . . . FEATURES &amp; BENEFITS . . . Soothes sore muscles . . . Soothes occasional tension . . . SUGGESTED USES . . . Apply topically to soothe sore muscle . . . Apply to neck and shoulders to soothe occasional tension . . . ABOUT . . . CBD Muscle Rub combines CBD, menthol, and a selection of Young Living premium essential oils such as Camphor, Clove, Lemon, Peppermint, Tea Tree, Wintergreen, and more. The result is a powerful balm that offers a cooling sensation and soothes sore muscles in seconds.” [from your webpage www.youngliving.com\u002Fus\u002Fen\u002Fproduct\u002Fcbd-muscle-rub]\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fnaturesultra.com\u003C\u002Fp>\n\n\u003Cp>• “Some studies suggest [t]he most common illnesses caused by an improperly functioning ECS are depression, Alzheimer[’]s, IBS, fibromyalgia, and even migraines . . . [t]hat’s why it’s so important to ensure that you are supporting it as needed . . . CBD [an ingredient in your Nature’s Ultra CBD Beauty Boost, Nature’s Ultra CBD Muscle Rub, Nature’s Ultra CBD Pep Bundle, Nature’s Ultra Calm CBD Roll-on, Nature’s Ultra Cinnamon CBD Oil, Nature’s Ultra Citrus CBD Oil, and Nature’s Ultra Cool Mint CBD Oil] is a great way to support your ECS . . ..” [from your webpage https:\u002F\u002Fnaturesultra.com\u002Fblogs\u002Fposts\u002Fhistory-of-the-endocannabinoid-system]\u003C\u002Fp>\n\n\u003Cp>• “When thinking of emotional wellness . . . [a] lot of people may think about mental health issues, such as depression or PTSD . . . [h]ow [c]an it be [i]mproved? . . . [y]ou can also try to encourage a positive and relaxing atmosphere throughout the day by using your favorite scents or oils! We highly recommend our Cinnamon CBD Oil.” [from your webpage https:\u002F\u002Fnaturesultra.com\u002Fblogs\u002Fposts\u002Femotional-strength]\u003C\u002Fp>\n\n\u003Cp>On the social media account www.facebook.com\u002Fessentialoilsaddict (EssentialOilsAddict) Tamara Rowe, Consultant #1744518)\u003Cbr>\n\u003Cbr>\n• December 21, 2018: “What does CBD oil support? . . . addiction . . . Alzheimer’s . . . anxiety . . . chronic pain . . . depression . . . diabetes . . . drug withdrawal . . . epilepsy . . . glaucoma . . . inflammation . . . insomnia . . . Parkinson’s . . . sleep disorders . . . plus more! . . . Coming Soon, Young Living CBD Oil”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the above claims, your \"Essential Oil\", \"Vitality\", “Ningxia”, and \"Nature's Ultra CBD\" products are drugs. We are not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that any of these products are generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended or suggested in their labeling. Accordingly, your \"Essential Oil\", \"Vitality\", “Ningxia”, and \"Nature's Ultra CBD\" products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug based on scientific data and information demonstrating that the drug is safe and effective. No FDA-approved application is in effect for any of these \"Essential Oil\", \"Vitality\", “Ningxia”, or \"Nature's Ultra CBD\" products. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the Act, 21 U.S.C. §§ 355(a), 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your \"Essential Oil\", \"Vitality\", “ Ningxia”, and \"Nature's Ultra CBD\" products are also misbranded within the meaning of section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. A drug is misbranded under section 502(f)(1) if the drug’s labeling fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended [21 CFR § 201.5]. Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner. Based on the above-referenced claims, your \"Essential Oil”, \"Vitality\", “Ningxia”, and \"Nature's Ultra CBD\" products are intended to prevent, treat, or cure conditions that are not amenable to self-diagnosis or treatment by individuals who are not medical practitioners, such as urinary tract infection, yeast infection, high cholesterol, high blood pressure, cancer, kidney stones, addiction, Alzheimer’s, anxiety, depression, chronic pain, diabetes, drug withdrawal, epilepsy, glaucoma, and Parkinson’s disease. Accordingly, your \"Essential Oil\", \"Vitality\", “Ningxia”, and \"Nature's Ultra CBD\" products are considered prescription drugs under section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)] and adequate directions for their use cannot be written so that a layperson can use these drugs safely for their intended purposes.\u003C\u002Fp>\n\n\u003Cp>Under 21 CFR §§ 201.100(c)(2) and 201.115, FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use, because no FDA-approved application is in effect for your products.\u003C\u002Fp>\n\n\u003Cp>Consequently, your \"Essential Oil\", \"Vitality\", “Ningxia”, and \"Nature's Ultra CBD\" products are misbranded drugs under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. § 352(f)(1).\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction into interstate commerce of misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CBD-containing Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Even if your \"Nature's Ultra CBD\" products were considered nonprescription drugs, we note that a nonprescription drug product containing CBD cannot be legally marketed without an approved new drug application, regardless of whether the CBD is represented on the labeling as an active ingredient or an inactive ingredient. To date, no CBD-containing drug has met applicable FDA requirements to be legally marketed for nonprescription use. Nonprescription drug products that include CBD as an active ingredient are not GRASE and are new drugs which require an approved application to be legally marketed. CBD is not an active ingredient in any OTC monograph under section 505G of the Act. Even if CBD could be considered an inactive ingredient in a nonprescription drug product, that product would still need an approved new drug application to be legally marketed, because the product would not meet the general requirements under section 505G of the Act under which certain nonprescription drug products may be marketed without an approved new drug application. In particular, such a product would not meet the general requirement with respect to the safety and suitability of inactive ingredients under 21 CFR § 330.1(e).\u003Csup>\u003Cem>\u003Cstrong>2,3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>In addition, we offer the following comment:\u003C\u002Fp>\n\n\u003Cp>• On the website www.stillbeingmolly.com (Molly Buckley Stillman, Consultant #1852080), under the Essential Oil category, in the “20 Uses for Frankincense Essential Oil” post: Number 15 states, “For new moms, apply one drop daily [of Frankincense Essential Oil] to the umbilical cord stump on your newborn until it falls off.” Please be aware that applying non-sterile, non-antimicrobial products topically to an umbilical cord may cause infection.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps that you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be addressed to the U.S. Food and Drug Administration; Attn: Hanna L. Potter, Compliance Officer; 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087 or via email at hanna.potter@fda.hhs.gov. You may reach Ms. Potter at (303) 236-3094 if you have any questions about this matter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>E. Mark Harris\u003Cbr>\nDistrict Director\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations –\u003Cbr>\nWest Division 4\u003Cbr>\n\u003Cbr>\nCc:\u003C\u002Fp>\n\n\u003Cp>Tiffaney Dwyer (Consultant #18682287)\u003Cbr>\n\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Madison Hollander (Consultant #12438030)\u003Cbr>\n\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Hannah Leiden-Olsen (Consultant #18682287)\u003Cbr>\n\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Tamar Rowe (Consultant #1744518)\u003Cbr>\n\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Molly Buckley Stillman (Consultant # 1852080)\u003Cbr>\n\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Carol Yeh-Garner (Consultant #1533467)\u003Cbr>\n\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>_______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> For example, under section 505G of the Act, 21 U.S.C. § 355h, certain nonprescription drug products may be lawfully marketed without an approved application if applicable conditions are met, including conformity with an applicable OTC monograph. However, your products could not be lawfully marketed under section 505G, because based on the above-referenced claims, your products are marketed for uses not considered nonprescription indications. Further, even if certain of your products, such as your Nature's Ultra CBD Muscle Rub, were marketed only for nonprescription indications, it would not meet the conditions under section 505G for lawful marketing without an approved application. For example, CBD—considered an active ingredient under 21 C.F.R. § 201.66(b)(2) due to its prominent featuring on the product labeling—is not an active ingredient in any OTC monograph under section 505G of the Act. Additionally, this product would be misbranded under section 502(ee) of the Act [21 U.S.C. § 352(ee)] because it would be a nonprescription drug subject to section 505G of the Act that does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the Act [21 U.S.C. § 355].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> 21 CFR § 330.1(e) requires in relevant part that \"the product contains only suitable inactive ingredients which are safe in the amounts administered\". A suitable inactive ingredient generally provides a beneficial formulation function, such as a tablet binder or preservative, or improves product delivery (e.g., enhances absorption or controls release of the drug substance). CBD has no known functional role as an inactive ingredient in a finished drug product.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Additionally, an inactive ingredient should not exert pharmacological effects and must be safe when used at the intended dosage. CBD has known pharmacological activity with demonstrated risks. For example, the labeling for Epidiolex (cannabidiol) prescription oral solution includes risks for the drug such as liver injury, interactions with other&nbsp;drugs or supplements, potential for male reproductive toxicity, somnolence, insomnia, diarrhea, decreased appetite, abdominal pain, upset stomach, changes in mood, irritability, and agitation. See \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf\u003C\u002Fa>. It is unknown whether the levels of CBD used in your CBD products have pharmacological activity or pose any concern for safety events.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMary B. Young\n\nRecipient Title\n\nCo-Founder and Chief Executive Officer\n\nYoung Living Essential Oils Corporate\n\n3125 W Executive Pkwy\n\nLehi, UT 84043\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations – West Division 4\n\nUnited States\n\nJune 10, 2022\n\nWARNING LETTER\n\nRE: 615777\n\nDear Mrs. Young:\n\nThis letter is to advise you that the Food and Drug Administration (FDA) reviewed your website and social media accounts (e.g., Instagram and Facebook) for several Young Living Consultants in May 2022 and has determined that your Young Living Consultants market many of your products, including, but not limited to, Frankincense Essential Oil, Lemon Essential Oil, Lavender Essential Oil, DiGize Essential Oil Blend, Thieves Essential Oil Blend (hereinafter \"Essential Oil\" products), Lemongrass Vitality, Peppermint Vitality (hereinafter \"Vitality\" products), Ningxia (hereinafter “Ningxia” product), Nature’s Ultra CBD Beauty Boost, Nature’s Ultra CBD Muscle Rub, Nature’s Ultra CBD Pep Bundle, Nature’s Ultra Calm CBD Roll-On, Nature’s Ultra Cinnamon CBD Oil, Nature’s Ultra Citrus CBD Oil, and Nature’s Ultra Cool Mint CBD Oil (hereinafter \"Nature's Ultra CBD\" products) and that you take orders for these products from your websites at the internet addresses www.youngliving.com and https:\u002F\u002Fnaturesultra.com.\n\nAdditionally, we have also reviewed social media accounts of your Young Living Consultants at www.stillbeingmolly.com, www.instagram.com\u002Fawelllivedlife, www.instagram.com\u002Fpeace.love.essentials, www.instagram.com\u002Fthehollanderhome, www.instagram.com\u002Ftiffaney_ann, and www.facebook.com\u002Fessentialoilsaddict. You market your Young Living “Essential Oil”, “Vitality”, “Ningxia”, and “Nature’s Ultra CBD” products through these paid consultants. Your compensation plan for your consultants is explained on your website at https:\u002F\u002Fwww.youngliving.com\u002Fus\u002Fen\u002Fcompany\u002Fcompensation-plan. Consumers interested in your products are then redirected by your consultants to your websites www.youngliving.com and www.naturesultra.com to purchase your products and\u002For register as “members” (i.e., consultants).\n\nYour \"Essential Oil\", \"Vitality\", “Ningxia”, and \"Nature's Ultra CBD\" products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. The intended use of a product may be determined by, among other things, its labeling, advertising, and the circumstances surrounding its distribution [21 C.F.R. § 201.128]. As explained further below, these products are also unapproved new drugs and misbranded drugs. Introducing or delivering these products for introduction into interstate commerce violates the Act. You can find the Act through links on FDA’s home page at www.fda.gov.\n\nExamples of claims found on your websites, as well as your Young Living Consultants’ social media account postings, that provide evidence of the intended uses of your products (as defined by 21 CFR § 201.128) as drugs include, but may not be limited to, the following:\n\n\"Essential Oil\" products\n\nOn the website www.stillbeingmolly.com (Molly Buckley Stillman, Consultant #1852080), under the Essential Oil category:\n\n• “20 Uses for Frankincense Essential Oil…”\n\no “16. May ease symptoms of discomfort from a urinary tract infection”\n\no “17. May ease symptoms of discomfort from a yeast infection”\n\no “19. Great to use … for a homemade sunscreen”\n\n• “30 Uses for Lemon Essential Oil...”\n\no “3…sometimes proves to be as effective as stone-breaking chanca piedra pills for the kidney stones.”\n\no “19. Use (especially along with lavender and peppermint) to ease those seasonal sniffles and runny noses”\n\no “23. Can be used to combat acne…”\n\no “24. May ease symptoms from urinary tract infections”\n\no “28. May reduce inflammation”\n\n• “35 Uses for Lavender Essential Oil…”\n\no “9. Use in a vegetable capsule, a teaspoon of honey … to ease those seasonal sniffles (especially this time of year with ALL of the pollen)”\n\nOn the social media account www.instagram.com\u002Fawelllivedlife (Carol Yeh-Garner, Consultant #1533467, Royal Crown Diamond Member)\n\n• May 24, 2020: “Phenolpropanoids… The Phenolpropanoids and phenols in essential oils… attack invading microbes and parasites…found in clove, peppermint [Vitality], fennel, basil and wintergreen.”\n\n• October 9, 2019: “…my friend…added me to a product education group where I learned that taking lemon [Essential Oil], lavender [Essential Oil] and peppermint [Vitality] could help with allergy symptoms like post-nasal drip, sneezing and itchy eyes…I used those oils to help with my allergies.”\n\nOn the social media account www.instagram.com\u002Fpeace.love.essentials (Hannah Leiden-Olsen, Consultant #18682287, Executive Member)\n\n• March 5, 2021: Video Image of Frankincense Essential Oil “…can help with arthritis…asthma…”\n\nOn the social media account www.instagram.com\u002Fthehollanderhome (Madison Hollander, Consultant #12438030)\n\n• March 9, 2020: “Digize [Essential Oil Blend]…heartburn”\n\nOn the social media account, www.instagram.com\u002Ftiffaney_ann (Tiffaney Dwyer, Consultant #2472927)\n\n• February 8, 2021: Image of Lavender Essential Oil – “Lavender-…Helps allergies…”\n\n• October 2, 2019: Thieves – “…a head cold. Sneezing, watering eyes, running\u002Fstuffed nose…even body aches…Today- however, I’m still feeling a little tired, my ears don’t hurt anymore, and I feel MUCH BETTER. The remedy, thieves [Essential Oil Blend] under the tongue all day long and an overdose of YL Vitamin C…ready to beat the cold and flu season…DM ME!!!”\n\n\"Vitality\" products\n\nOn the social media account www.instagram.com\u002Fthehollanderhome (Madison Hollander, Consultant #12438030)\n\n• July 28, 2020: Image of Lemongrass Vitality – “Lemongrass poses a very strong argument for being the ‘go-to’ when you find yourself not feeling well, battling inflammation, infection, stomach upset, stuffy sinuses…high body temps…high blood pressure, high cholesterol…If it’s stomach upset, bladder discomfort, cholesterol, or blood pressure that we are looking to improve, we ingest.”\n\n• March 9, 2020: “Peppermint [Vitality]…headache…”\n\n“Ningxia” product\n\nOn the social media account www.instagram.com\u002Fthehollanderhome (Madison Hollander, Consultant #12438030)\n\n• December 1, 2020: Image of Ningxia – “Ningxia - scientifically proven to be the highest antioxidant food source in the world…Inflammation, disease, and cancer are all driven by Free Radicals…Antioxidants neutralize free radicals, meaning they stop them from doing damage… reduced inflammation, healthy cholesterol and blood sugar.”\n\nOn the social media account www.instagram.com\u002Ftiffaney_ann (Tiffaney Dwyer, Consultant #2472927)\n\n• January 14, 2020: Ningxia – “…we’ve had Ningxia as part of our daily routine, we don’t get the flu, when we get a cold it’s not that bad at all and it’s short lived…”\n\n\"Nature's Ultra CBD\" products\n\nOn your website www.youngliving.com\n\n• “CBD MUSCLE RUB . . . FEATURES & BENEFITS . . . Soothes sore muscles . . . Soothes occasional tension . . . SUGGESTED USES . . . Apply topically to soothe sore muscle . . . Apply to neck and shoulders to soothe occasional tension . . . ABOUT . . . CBD Muscle Rub combines CBD, menthol, and a selection of Young Living premium essential oils such as Camphor, Clove, Lemon, Peppermint, Tea Tree, Wintergreen, and more. The result is a powerful balm that offers a cooling sensation and soothes sore muscles in seconds.” [from your webpage www.youngliving.com\u002Fus\u002Fen\u002Fproduct\u002Fcbd-muscle-rub]\n\nOn your website https:\u002F\u002Fnaturesultra.com\n\n• “Some studies suggest [t]he most common illnesses caused by an improperly functioning ECS are depression, Alzheimer[’]s, IBS, fibromyalgia, and even migraines . . . [t]hat’s why it’s so important to ensure that you are supporting it as needed . . . CBD [an ingredient in your Nature’s Ultra CBD Beauty Boost, Nature’s Ultra CBD Muscle Rub, Nature’s Ultra CBD Pep Bundle, Nature’s Ultra Calm CBD Roll-on, Nature’s Ultra Cinnamon CBD Oil, Nature’s Ultra Citrus CBD Oil, and Nature’s Ultra Cool Mint CBD Oil] is a great way to support your ECS . . ..” [from your webpage https:\u002F\u002Fnaturesultra.com\u002Fblogs\u002Fposts\u002Fhistory-of-the-endocannabinoid-system]\n\n• “When thinking of emotional wellness . . . [a] lot of people may think about mental health issues, such as depression or PTSD . . . [h]ow [c]an it be [i]mproved? . . . [y]ou can also try to encourage a positive and relaxing atmosphere throughout the day by using your favorite scents or oils! We highly recommend our Cinnamon CBD Oil.” [from your webpage https:\u002F\u002Fnaturesultra.com\u002Fblogs\u002Fposts\u002Femotional-strength]\n\nOn the social media account www.facebook.com\u002Fessentialoilsaddict (EssentialOilsAddict) Tamara Rowe, Consultant #1744518)\n\n• December 21, 2018: “What does CBD oil support? . . . addiction . . . Alzheimer’s . . . anxiety . . . chronic pain . . . depression . . . diabetes . . . drug withdrawal . . . epilepsy . . . glaucoma . . . inflammation . . . insomnia . . . Parkinson’s . . . sleep disorders . . . plus more! . . . Coming Soon, Young Living CBD Oil”\n\nUnapproved New Drugs\n\nBased on the above claims, your \"Essential Oil\", \"Vitality\", “Ningxia”, and \"Nature's Ultra CBD\" products are drugs. We are not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that any of these products are generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended or suggested in their labeling. Accordingly, your \"Essential Oil\", \"Vitality\", “Ningxia”, and \"Nature's Ultra CBD\" products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here1, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug based on scientific data and information demonstrating that the drug is safe and effective. No FDA-approved application is in effect for any of these \"Essential Oil\", \"Vitality\", “Ningxia”, or \"Nature's Ultra CBD\" products. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the Act, 21 U.S.C. §§ 355(a), 331(d).\n\nMisbranded Drugs\n\nYour \"Essential Oil\", \"Vitality\", “ Ningxia”, and \"Nature's Ultra CBD\" products are also misbranded within the meaning of section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. A drug is misbranded under section 502(f)(1) if the drug’s labeling fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended [21 CFR § 201.5]. Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner. Based on the above-referenced claims, your \"Essential Oil”, \"Vitality\", “Ningxia”, and \"Nature's Ultra CBD\" products are intended to prevent, treat, or cure conditions that are not amenable to self-diagnosis or treatment by individuals who are not medical practitioners, such as urinary tract infection, yeast infection, high cholesterol, high blood pressure, cancer, kidney stones, addiction, Alzheimer’s, anxiety, depression, chronic pain, diabetes, drug withdrawal, epilepsy, glaucoma, and Parkinson’s disease. Accordingly, your \"Essential Oil\", \"Vitality\", “Ningxia”, and \"Nature's Ultra CBD\" products are considered prescription drugs under section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)] and adequate directions for their use cannot be written so that a layperson can use these drugs safely for their intended purposes.\n\nUnder 21 CFR §§ 201.100(c)(2) and 201.115, FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use, because no FDA-approved application is in effect for your products.\n\nConsequently, your \"Essential Oil\", \"Vitality\", “Ningxia”, and \"Nature's Ultra CBD\" products are misbranded drugs under section 502(f)(1) of the FD&C Act, 21 U.S.C. § 352(f)(1).\n\nThe introduction or delivery for introduction into interstate commerce of misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nCBD-containing Drugs\n\nEven if your \"Nature's Ultra CBD\" products were considered nonprescription drugs, we note that a nonprescription drug product containing CBD cannot be legally marketed without an approved new drug application, regardless of whether the CBD is represented on the labeling as an active ingredient or an inactive ingredient. To date, no CBD-containing drug has met applicable FDA requirements to be legally marketed for nonprescription use. Nonprescription drug products that include CBD as an active ingredient are not GRASE and are new drugs which require an approved application to be legally marketed. CBD is not an active ingredient in any OTC monograph under section 505G of the Act. Even if CBD could be considered an inactive ingredient in a nonprescription drug product, that product would still need an approved new drug application to be legally marketed, because the product would not meet the general requirements under section 505G of the Act under which certain nonprescription drug products may be marketed without an approved new drug application. In particular, such a product would not meet the general requirement with respect to the safety and suitability of inactive ingredients under 21 CFR § 330.1(e).2,3\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nIn addition, we offer the following comment:\n\n• On the website www.stillbeingmolly.com (Molly Buckley Stillman, Consultant #1852080), under the Essential Oil category, in the “20 Uses for Frankincense Essential Oil” post: Number 15 states, “For new moms, apply one drop daily [of Frankincense Essential Oil] to the umbilical cord stump on your newborn until it falls off.” Please be aware that applying non-sterile, non-antimicrobial products topically to an umbilical cord may cause infection.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps that you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour reply should be addressed to the U.S. Food and Drug Administration; Attn: Hanna L. Potter, Compliance Officer; 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087 or via email at hanna.potter@fda.hhs.gov. You may reach Ms. Potter at (303) 236-3094 if you have any questions about this matter.\n\nSincerely,\n\n\u002FS\u002F\n\nE. Mark Harris\n\nDistrict Director\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations –\n\nWest Division 4\n\nCc:\n\nTiffaney Dwyer (Consultant #18682287)\n\n(b)(6)\n\nMadison Hollander (Consultant #12438030)\n\n(b)(6)\n\nHannah Leiden-Olsen (Consultant #18682287)\n\n(b)(6)\n\nTamar Rowe (Consultant #1744518)\n\n(b)(6)\n\nMolly Buckley Stillman (Consultant # 1852080)\n\n(b)(6)\n\nCarol Yeh-Garner (Consultant #1533467)\n\n(b)(6)\n\n_______________________________\n\n1 For example, under section 505G of the Act, 21 U.S.C. § 355h, certain nonprescription drug products may be lawfully marketed without an approved application if applicable conditions are met, including conformity with an applicable OTC monograph. However, your products could not be lawfully marketed under section 505G, because based on the above-referenced claims, your products are marketed for uses not considered nonprescription indications. Further, even if certain of your products, such as your Nature's Ultra CBD Muscle Rub, were marketed only for nonprescription indications, it would not meet the conditions under section 505G for lawful marketing without an approved application. For example, CBD—considered an active ingredient under 21 C.F.R. § 201.66(b)(2) due to its prominent featuring on the product labeling—is not an active ingredient in any OTC monograph under section 505G of the Act. Additionally, this product would be misbranded under section 502(ee) of the Act [21 U.S.C. § 352(ee)] because it would be a nonprescription drug subject to section 505G of the Act that does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the Act [21 U.S.C. § 355].\n\n2 21 CFR § 330.1(e) requires in relevant part that \"the product contains only suitable inactive ingredients which are safe in the amounts administered\". A suitable inactive ingredient generally provides a beneficial formulation function, such as a tablet binder or preservative, or improves product delivery (e.g., enhances absorption or controls release of the drug substance). CBD has no known functional role as an inactive ingredient in a finished drug product.\n\n3 Additionally, an inactive ingredient should not exert pharmacological effects and must be safe when used at the intended dosage. CBD has known pharmacological activity with demonstrated risks. For example, the labeling for Epidiolex (cannabidiol) prescription oral solution includes risks for the drug such as liver injury, interactions with other drugs or supplements, potential for male reproductive toxicity, somnolence, insomnia, diarrhea, decreased appetite, abdominal pain, upset stomach, changes in mood, irritability, and agitation. See https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf. It is unknown whether the levels of CBD used in your CBD products have pharmacological activity or pose any concern for safety events.","Young Living Essential Oils Corporate","young-living-essential-oils-corporate-615777-06102022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fyoung-living-essential-oils-corporate-615777-06102022","2026-10-26T08:10:37.483066+00:00","2022-07-19","615777","Mary B. Young","2026-08-20T01:45:57.789+00:00","VIA UPS","2022-06-10",{"id":230,"raw":231,"subject":40,"body_html":235,"body_text":236,"firm_name":237,"letter_id":238,"created_at":67,"fei_number":19,"letter_url":239,"updated_at":240,"action_type":22,"case_status":23,"posted_date":241,"marcs_cms_no":242,"product_type":50,"closeout_date":19,"issuing_office":38,"recipient_name":243,"body_fetched_at":244,"delivery_method":53,"recipient_title":19,"reference_number":19,"action_taken_date":245,"medical_device_id":19,"response_letter_date":19},3143,[232,233,234,38,40,13,13,13],"\u003Ctime datetime=\"2021-09-14T13:20:00Z\">09\u002F14\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-02T04:00:00Z\">09\u002F02\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fweidenhamer-and-morin-enterprises-llc-dba-liquivape-616816-09022021\">Weidenhamer and Morin Enterprises LLC d\u002Fb\u002Fa Liquivape\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael Weidenhamer and Timothy Morin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Weidenhamer and Morin Enterprises LLC d\u002Fb\u002Fa Liquivape\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>67 South Lake Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Forest Lake\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55025\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Michael Weidenhamer and Timothy Morin:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.liquivapeus.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.liquivapeus.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Liquivape Gummi Bearz and Liquivape Swedish Phish.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 1,000 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2101625, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Liquivape\u003Cbr>\n1318 Vermillion St\u003Cbr>\nHastings, MN 55033\u003C\u002Fp>\n\n\u003Cp>Liquivape\u003Cbr>\n1412 Tower Ave\u003Cbr>\nSuper, WI 54880\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nMichael Weidenhamer and Timothy Morin\n\nWeidenhamer and Morin Enterprises LLC d\u002Fb\u002Fa Liquivape\n\n67 South Lake Street\n\nForest Lake, MN 55025\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Michael Weidenhamer and Timothy Morin:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.liquivapeus.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.liquivapeus.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Liquivape Gummi Bearz and Liquivape Swedish Phish.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 1,000 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101625, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nLiquivape\n\n1318 Vermillion St\n\nHastings, MN 55033\n\nLiquivape\n\n1412 Tower Ave\n\nSuper, WI 54880\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\n(b)(6)","Weidenhamer and Morin Enterprises LLC d\u002Fb\u002Fa Liquivape","weidenhamer-and-morin-enterprises-llc-dba-liquivape-616816-09022021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fweidenhamer-and-morin-enterprises-llc-dba-liquivape-616816-09022021","2026-10-26T08:10:30.852821+00:00","2021-09-14","616816","Michael Weidenhamer and Timothy Morin","2026-08-20T02:36:18.497+00:00","2021-09-02",{"id":247,"raw":248,"subject":253,"body_html":254,"body_text":255,"firm_name":256,"letter_id":257,"created_at":125,"fei_number":19,"letter_url":258,"updated_at":259,"action_type":22,"case_status":23,"posted_date":260,"marcs_cms_no":261,"product_type":26,"closeout_date":19,"issuing_office":252,"recipient_name":262,"body_fetched_at":263,"delivery_method":75,"recipient_title":19,"reference_number":19,"action_taken_date":264,"medical_device_id":19,"response_letter_date":19},2240,[249,250,251,252,253,13,13,13],"\u003Ctime datetime=\"2023-01-24T14:20:00Z\">01\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-11T05:00:00Z\">01\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flarkin-community-hospital-institutional-review-board-638146-01112023\">Larkin Community Hospital Institutional Review Board\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Bioresearch Monitoring Program\u002FInstitutional Review Board (IRB)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>(b)(6)\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President for Research and Academic Affairs\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Larkin Community Hospital Institutional Review Board\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7031 Southwest 62nd Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Miami\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33143-4701\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 11, 2023\u003C\u002Fp>\n\n\u003Cp>FDA Ref. No.: 23-HFD-45-01-01\u003C\u002Fp>\n\n\u003Cp>Dear \u003Cstrong>(b)(6)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between November 12 and November 19, 2021, of the Larkin Community Hospital Institutional Review Board (IRB). Investigator Richard A. Lyght, representing FDA, conducted the inspection to determine whether the IRB’s procedures for the protection of human subjects complied with FDA regulations contained in Title 21 of the Code of Federal Regulations (CFR), parts 50 and 56. These regulations apply to clinical investigations of products regulated by FDA.\u003C\u002Fp>\n\n\u003Cp>This inspection is a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, Investigator Lyght presented and discussed with you Form FDA 483, Inspectional Observations. We acknowledge receipt of the IRB’s December 6, 2021, written response to the Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and the IRB’s December 6, 2021, written response, it appears that the IRB did not adhere to applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and FDA regulations governing the protection of human subjects.\u003C\u002Fp>\n\n\u003Cp>We wish to emphasize the following:\u003Cbr>\n\u003Cbr>\n\u003Cstrong>1. The IRB failed to review proposed research at convened meetings at which a majority of the members of the IRB are present, including at least one member whose primary concerns are in nonscientific areas [21 CFR 56.108(c)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under 21 CFR 56.108(c), except when an expedited review procedure is used, the IRB may review proposed research only at convened meetings at which a majority of the IRB members are present, including at least one member whose primary concerns are in nonscientific areas. The IRB failed to adhere to this requirement.\u003C\u002Fp>\n\n\u003Cp>Specifically, the IRB reviewed and approved FDA-regulated research at convened IRB meetings where a majority of the IRB members, including at least one nonscientist member, were not present.\u003C\u002Fp>\n\n\u003Cp>IRB meeting minutes for meetings held on April 24, 2020; August 3, 2020; September 11, 2020; November 16, 2020; and February 15, 2021, indicate that the following members were present, and that no member whose primary concerns are in nonscientific areas attended:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>IRB meeting held on April 24, 2020: Gerardo Ferrer (physician), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (physician), and \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist)\u003C\u002Fli>\n\t\u003Cli>IRB meeting held on August 3, 2020: Gerardo F. Ferrer (physician), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (physician), and \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist)\u003C\u002Fli>\n\t\u003Cli>IRB meeting held on September 11, 2020: Gerardo F. Ferrer (physician), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (physician), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (physician), and \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist)\u003C\u002Fli>\n\t\u003Cli>IRB meeting held on November 16, 2020: \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (physician), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (physician), and \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist)\u003C\u002Fli>\n\t\u003Cli>IRB meeting held on February 15, 2021: Gerardo F. Ferrer (physician), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (physician), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (physician), and \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist)\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The IRB should not have reviewed or approved the proposed research because the IRB did not have a member present whose primary concerns are in nonscientific areas at these IRB meetings in which FDA-regulated research was reviewed.\u003C\u002Fp>\n\n\u003Cp>During the inspection, the IRB chair, Gerardo F. Ferrer, M.D., indicated that \u003Cstrong>(b)(6)\u003C\u002Fstrong> acted as the nonscientific IRB member. However, Ms. \u003Cstrong>(b)(6)\u003C\u002Fstrong> resigned on April 24, 2020, and was not in attendance at any of the above-mentioned IRB meetings. Furthermore, no other nonscientific member appears to have been identified or attended any of the above-mentioned IRB meetings.\u003C\u002Fp>\n\n\u003Cp>In your December 6, 2021, written response to the Form FDA 483, you indicated that this observation has been noted and procedures are being initiated to correct this observation. In addition, you indicated that IRB meetings will only take place if a majority of the IRB members are available, including one nonscientific member. You also stated that the IRB minute agendas will document members’ affiliations to facilitate audit review designation.\u003C\u002Fp>\n\n\u003Cp>We are unable to perform an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details on the procedures you are initiating and how you will ensure that a majority of the IRB members, including at least one member whose primary concerns are in nonscientific areas, will be present at convened meetings when proposed FDA-regulated research is under review.\u003C\u002Fp>\n\n\u003Cp>As an IRB, review of proposed research at convened meetings at which a majority of the IRB members is present, including at least one member whose primary concerns are in a nonscientific area, is important to ensure that the IRB’s review and approval of research is fair and equitable.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. The IRB failed to prepare and maintain adequate documentation of IRB activities, including a list of IRB members [21 CFR 56.115(a)(5)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under 21 CFR 56.115(a), the IRB is required to prepare and maintain adequate documentation of IRB activities, including a list of IRB members identified by name; earned degrees; representative capacity; indications of experience such as board certifications, licenses, etc., sufficient to describe each member’s chief anticipated contributions to IRB deliberations; and any employment or other relationship between each member and the institution. The IRB failed to adhere to these requirements.\u003C\u002Fp>\n\n\u003Cp>Specifically, the IRB failed to prepare and maintain a list of IRB members, in accordance with 21 CFR 56.115(a)(5), for the time period between July 2019 and March 2021. During the inspection, the IRB compiled a membership list for this time frame. However, this list is inadequate because it did not include all IRB members listed in minutes for IRB meetings convened during this time frame. Furthermore, for several listed IRB members, the list did not include each IRB member’s representative capacity, indications of experience sufficient to describe the member’s chief anticipated contributions to the IRB deliberations, or any employment or other relationship between the member and the institution. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(6)\u003C\u002Fstrong>, M.D., M.B.A., F.A.C.S., is not listed on this membership list, but is listed as a voting member in the minutes of the IRB meetings held on September 11, 2020; November 16, 2020; and February 15, 2021.\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(6)\u003C\u002Fstrong>, M.S., L.M.H.C., C.A.P., is not listed on this membership list, but is listed as an absent voting member in the minutes of the IRB meetings held on April 24, 2020; August 3, 2020; September 11, 2020; and February 15, 2021.\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(6)\u003C\u002Fstrong>, M.D., M.S.S., is listed on this membership list, but this IRB member’s representative capacity is missing.\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(6)\u003C\u002Fstrong>, Pharm.D., M.P.H., B.C.P.S., is listed on this membership list, but this IRB member’s representative capacity is missing.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your December 6, 2021, written response to the Form FDA 483, you noted the observation and stated that it was difficult to acquire in full details the complete membership list because the prior IRB coordinator’s files were not easily accessible. You noted that a new roster of current members will be created, maintained, monitored annually, and adjusted when required. You also indicated that the membership list will include the full details of each member’s name, earned degrees, representative capacity, and indication of experience sufficient to describe the member’s chief anticipated contribution to IRB deliberations. However, we note that this membership list, as proposed, would not meet the regulatory requirements unless employment or other relationship between each member and the institution were to be included, as required under 21 CFR 56.115(a)(5).\u003C\u002Fp>\n\n\u003Cp>We are unable to undertake an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details on the actions that will be taken (for example, maintaining and monitoring the new membership list annually) to ensure that the IRB prepares and maintains a list of IRB members in accordance with the regulations at 21 CFR 56.115(a)(5). In addition, you did not provide documentation of a complete, updated membership list that includes the missing information described above. Please submit a current membership list that complies with 21 CFR 56.115(a)(5).\u003C\u002Fp>\n\n\u003Cp>As an IRB, you are required to prepare and maintain a complete list of IRB members in compliance with 21 CFR 56.115(a)(5) to ensure that the IRB has adequate representation, experience, and expertise to promote complete and adequate review of the institution’s research activities.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. The IRB failed to ensure that information given to subjects as part of informed consent is in accordance with 21 CFR part 50.25 [21 CFR 56.109(b)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under 21 CFR 56.109(b), the IRB must require that information given to subjects as part of the informed consent process is in accordance with 21 CFR 50.25 (elements of informed consent). The IRB failed to ensure that the IRB-approved informed consent documents (ICDs) for the following two clinical trials, which meet the definition of an “applicable drug clinical trial”\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, contained the statement\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> notifying the subject that clinical trial information has been or will be submitted for inclusion in the clinical trial registry databank, as required by 21 CFR 50.25(c):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Protocol LCH-2-112020, “Impact of GSE and Xylitol (Xlear) in Symptoms and time to PCR negativisation of patients with Acute COVID-19 Infection”\u003C\u002Fli>\n\t\u003Cli>Protocol LCH-3-082020, “A Randomized Placebo Control Trial to Evaluate the Efficacy of Xylitol Nasal Sprays vs. Placebo for Acute COVID-19 Infection”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your December 6, 2021, written response, you noted the observation and stated that actions were in motion to establish best practices. You also indicated that the formatted informed consent will contain the statement for clinical trials, as required by 21 CFR 50.25(c).\u003C\u002Fp>\n\n\u003Cp>We acknowledge your written response, indicating that “actions are in motion to establish best practice” and that ICDs will contain the required information. However, we are unable to perform an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details on the best practices you are establishing and how you will ensure that the ICDs will contain the statement, as required by 21 CFR 50.25(c), when appropriate.\u003C\u002Fp>\n\n\u003Cp>Failure to ensure that IRB-approved informed consent documents for applicable clinical trials contain the statement notifying subjects that clinical trial information has been or will be submitted for inclusion in the clinical trial registry databank may result in subjects not being provided appropriate human subject research protections or pertinent information about the clinical investigation.\u003C\u002Fp>\n\n\u003Cp>For more information on this element, please see “Guidance for Sponsors, Investigators, and Institutional Review Boards: Questions and Answers on Informed Consent Elements, 21 CFR § 50.25(c)” at the following URL:&nbsp;\u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FRegulatoryInformation\u002FGuidances\u002FUCM291085.pdf\">http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FRegulatoryInformation\u002FGuidances\u002FUCM291085.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies related to the IRB’s procedures or the review and approval by the IRB of protocols and informed consent documents. It is the IRB’s responsibility to ensure adherence to each requirement of the law and relevant FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions the IRB plans to take or has taken to address any violations and to prevent recurrence of similar violations in the future. Failure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>We recommend that the IRB visit the following FDA Web page for information on human subject protections that may assist the IRB in its efforts to come into compliance with FDA regulations:&nbsp;\u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FScienceResearch\u002FSpecialTopics\u002FRunningClinicalTrials\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FScienceResearch\u002FSpecialTopics\u002FRunningClinicalTrials\u002Fdefault.htm\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>If the IRB has any questions, please call Miah Jung, Pharm.D., M.S., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. The IRB’s written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\n\n\u003Cp>Miah Jung, Pharm.D., M.S.\u003Cbr>\nBranch Chief\u003Cbr>\nCompliance Enforcement Branch\u003Cbr>\nDivision of Enforcement and Postmarketing Safety\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nBuilding 51, Room 5352\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>David C. Burrow, Pharm.D., J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See 42 USC 282(j)(1)(A) and 42 CFR 11.10 for the definition of “applicable drug clinical trial.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> “A description of this clinical trial will be available on http:\u002F\u002Fwww.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.”\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\n(b)(6)\n\nRecipient Title\n\nVice President for Research and Academic Affairs\n\nLarkin Community Hospital Institutional Review Board\n\n7031 Southwest 62nd Avenue\n\nSouth Miami, FL 33143-4701\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nJanuary 11, 2023\n\nFDA Ref. No.: 23-HFD-45-01-01\n\nDear (b)(6):\n\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between November 12 and November 19, 2021, of the Larkin Community Hospital Institutional Review Board (IRB). Investigator Richard A. Lyght, representing FDA, conducted the inspection to determine whether the IRB’s procedures for the protection of human subjects complied with FDA regulations contained in Title 21 of the Code of Federal Regulations (CFR), parts 50 and 56. These regulations apply to clinical investigations of products regulated by FDA.\n\nThis inspection is a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\n\nAt the conclusion of the inspection, Investigator Lyght presented and discussed with you Form FDA 483, Inspectional Observations. We acknowledge receipt of the IRB’s December 6, 2021, written response to the Form FDA 483.\n\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and the IRB’s December 6, 2021, written response, it appears that the IRB did not adhere to applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and FDA regulations governing the protection of human subjects.\n\nWe wish to emphasize the following:\n\n1. The IRB failed to review proposed research at convened meetings at which a majority of the members of the IRB are present, including at least one member whose primary concerns are in nonscientific areas [21 CFR 56.108(c)].\n\nUnder 21 CFR 56.108(c), except when an expedited review procedure is used, the IRB may review proposed research only at convened meetings at which a majority of the IRB members are present, including at least one member whose primary concerns are in nonscientific areas. The IRB failed to adhere to this requirement.\n\nSpecifically, the IRB reviewed and approved FDA-regulated research at convened IRB meetings where a majority of the IRB members, including at least one nonscientist member, were not present.\n\nIRB meeting minutes for meetings held on April 24, 2020; August 3, 2020; September 11, 2020; November 16, 2020; and February 15, 2021, indicate that the following members were present, and that no member whose primary concerns are in nonscientific areas attended:\n\nIRB meeting held on April 24, 2020: Gerardo Ferrer (physician), (b)(6) (pharmacist), (b)(6) (physician), and (b)(6) (pharmacist)\n\nIRB meeting held on August 3, 2020: Gerardo F. Ferrer (physician), (b)(6) (pharmacist), (b)(6) (physician), and (b)(6) (pharmacist)\n\nIRB meeting held on September 11, 2020: Gerardo F. Ferrer (physician), (b)(6) (pharmacist), (b)(6) (physician), (b)(6) (physician), and (b)(6) (pharmacist)\n\nIRB meeting held on November 16, 2020: (b)(6) (pharmacist), (b)(6) (physician), (b)(6) (physician), and (b)(6) (pharmacist)\n\nIRB meeting held on February 15, 2021: Gerardo F. Ferrer (physician), (b)(6) (pharmacist), (b)(6) (physician), (b)(6) (physician), and (b)(6) (pharmacist)\n\nThe IRB should not have reviewed or approved the proposed research because the IRB did not have a member present whose primary concerns are in nonscientific areas at these IRB meetings in which FDA-regulated research was reviewed.\n\nDuring the inspection, the IRB chair, Gerardo F. Ferrer, M.D., indicated that (b)(6) acted as the nonscientific IRB member. However, Ms. (b)(6) resigned on April 24, 2020, and was not in attendance at any of the above-mentioned IRB meetings. Furthermore, no other nonscientific member appears to have been identified or attended any of the above-mentioned IRB meetings.\n\nIn your December 6, 2021, written response to the Form FDA 483, you indicated that this observation has been noted and procedures are being initiated to correct this observation. In addition, you indicated that IRB meetings will only take place if a majority of the IRB members are available, including one nonscientific member. You also stated that the IRB minute agendas will document members’ affiliations to facilitate audit review designation.\n\nWe are unable to perform an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details on the procedures you are initiating and how you will ensure that a majority of the IRB members, including at least one member whose primary concerns are in nonscientific areas, will be present at convened meetings when proposed FDA-regulated research is under review.\n\nAs an IRB, review of proposed research at convened meetings at which a majority of the IRB members is present, including at least one member whose primary concerns are in a nonscientific area, is important to ensure that the IRB’s review and approval of research is fair and equitable.\n\n2. The IRB failed to prepare and maintain adequate documentation of IRB activities, including a list of IRB members [21 CFR 56.115(a)(5)].\n\nUnder 21 CFR 56.115(a), the IRB is required to prepare and maintain adequate documentation of IRB activities, including a list of IRB members identified by name; earned degrees; representative capacity; indications of experience such as board certifications, licenses, etc., sufficient to describe each member’s chief anticipated contributions to IRB deliberations; and any employment or other relationship between each member and the institution. The IRB failed to adhere to these requirements.\n\nSpecifically, the IRB failed to prepare and maintain a list of IRB members, in accordance with 21 CFR 56.115(a)(5), for the time period between July 2019 and March 2021. During the inspection, the IRB compiled a membership list for this time frame. However, this list is inadequate because it did not include all IRB members listed in minutes for IRB meetings convened during this time frame. Furthermore, for several listed IRB members, the list did not include each IRB member’s representative capacity, indications of experience sufficient to describe the member’s chief anticipated contributions to the IRB deliberations, or any employment or other relationship between the member and the institution. For example:\n\n(b)(6), M.D., M.B.A., F.A.C.S., is not listed on this membership list, but is listed as a voting member in the minutes of the IRB meetings held on September 11, 2020; November 16, 2020; and February 15, 2021.\n\n(b)(6), M.S., L.M.H.C., C.A.P., is not listed on this membership list, but is listed as an absent voting member in the minutes of the IRB meetings held on April 24, 2020; August 3, 2020; September 11, 2020; and February 15, 2021.\n\n(b)(6), M.D., M.S.S., is listed on this membership list, but this IRB member’s representative capacity is missing.\n\n(b)(6), Pharm.D., M.P.H., B.C.P.S., is listed on this membership list, but this IRB member’s representative capacity is missing.\n\nIn your December 6, 2021, written response to the Form FDA 483, you noted the observation and stated that it was difficult to acquire in full details the complete membership list because the prior IRB coordinator’s files were not easily accessible. You noted that a new roster of current members will be created, maintained, monitored annually, and adjusted when required. You also indicated that the membership list will include the full details of each member’s name, earned degrees, representative capacity, and indication of experience sufficient to describe the member’s chief anticipated contribution to IRB deliberations. However, we note that this membership list, as proposed, would not meet the regulatory requirements unless employment or other relationship between each member and the institution were to be included, as required under 21 CFR 56.115(a)(5).\n\nWe are unable to undertake an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details on the actions that will be taken (for example, maintaining and monitoring the new membership list annually) to ensure that the IRB prepares and maintains a list of IRB members in accordance with the regulations at 21 CFR 56.115(a)(5). In addition, you did not provide documentation of a complete, updated membership list that includes the missing information described above. Please submit a current membership list that complies with 21 CFR 56.115(a)(5).\n\nAs an IRB, you are required to prepare and maintain a complete list of IRB members in compliance with 21 CFR 56.115(a)(5) to ensure that the IRB has adequate representation, experience, and expertise to promote complete and adequate review of the institution’s research activities.\n\n3. The IRB failed to ensure that information given to subjects as part of informed consent is in accordance with 21 CFR part 50.25 [21 CFR 56.109(b)].\n\nUnder 21 CFR 56.109(b), the IRB must require that information given to subjects as part of the informed consent process is in accordance with 21 CFR 50.25 (elements of informed consent). The IRB failed to ensure that the IRB-approved informed consent documents (ICDs) for the following two clinical trials, which meet the definition of an “applicable drug clinical trial”1, contained the statement2 notifying the subject that clinical trial information has been or will be submitted for inclusion in the clinical trial registry databank, as required by 21 CFR 50.25(c):\n\nProtocol LCH-2-112020, “Impact of GSE and Xylitol (Xlear) in Symptoms and time to PCR negativisation of patients with Acute COVID-19 Infection”\n\nProtocol LCH-3-082020, “A Randomized Placebo Control Trial to Evaluate the Efficacy of Xylitol Nasal Sprays vs. Placebo for Acute COVID-19 Infection”\n\nIn your December 6, 2021, written response, you noted the observation and stated that actions were in motion to establish best practices. You also indicated that the formatted informed consent will contain the statement for clinical trials, as required by 21 CFR 50.25(c).\n\nWe acknowledge your written response, indicating that “actions are in motion to establish best practice” and that ICDs will contain the required information. However, we are unable to perform an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details on the best practices you are establishing and how you will ensure that the ICDs will contain the statement, as required by 21 CFR 50.25(c), when appropriate.\n\nFailure to ensure that IRB-approved informed consent documents for applicable clinical trials contain the statement notifying subjects that clinical trial information has been or will be submitted for inclusion in the clinical trial registry databank may result in subjects not being provided appropriate human subject research protections or pertinent information about the clinical investigation.\n\nFor more information on this element, please see “Guidance for Sponsors, Investigators, and Institutional Review Boards: Questions and Answers on Informed Consent Elements, 21 CFR § 50.25(c)” at the following URL: http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FRegulatoryInformation\u002FGuidances\u002FUCM291085.pdf.\n\nThis letter is not intended to be an all-inclusive list of deficiencies related to the IRB’s procedures or the review and approval by the IRB of protocols and informed consent documents. It is the IRB’s responsibility to ensure adherence to each requirement of the law and relevant FDA regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions the IRB plans to take or has taken to address any violations and to prevent recurrence of similar violations in the future. Failure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\n\nWe recommend that the IRB visit the following FDA Web page for information on human subject protections that may assist the IRB in its efforts to come into compliance with FDA regulations: http:\u002F\u002Fwww.fda.gov\u002FScienceResearch\u002FSpecialTopics\u002FRunningClinicalTrials\u002Fdefault.htm.\n\nIf the IRB has any questions, please call Miah Jung, Pharm.D., M.S., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. The IRB’s written response and any pertinent documentation should be addressed to:\n\nMiah Jung, Pharm.D., M.S.\n\nBranch Chief\n\nCompliance Enforcement Branch\n\nDivision of Enforcement and Postmarketing Safety\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\nBuilding 51, Room 5352\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993\n\nSincerely yours,\n\n\u002FS\u002F\n\nDavid C. Burrow, Pharm.D., J.D.\n\nDirector\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n__________________________\n\n1 See 42 USC 282(j)(1)(A) and 42 CFR 11.10 for the definition of “applicable drug clinical trial.”\n\n2 “A description of this clinical trial will be available on http:\u002F\u002Fwww.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.”","Larkin Community Hospital Institutional Review Board","larkin-community-hospital-institutional-review-board-638146-01112023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flarkin-community-hospital-institutional-review-board-638146-01112023","2026-10-26T08:09:12.420022+00:00","2023-01-24","638146","(b)(6)","2026-08-20T01:18:23.294+00:00","2023-01-11",{"id":266,"raw":267,"subject":12,"body_html":271,"body_text":272,"firm_name":273,"letter_id":274,"created_at":18,"fei_number":19,"letter_url":275,"updated_at":276,"action_type":22,"case_status":23,"posted_date":277,"marcs_cms_no":278,"product_type":26,"closeout_date":19,"issuing_office":252,"recipient_name":279,"body_fetched_at":280,"delivery_method":30,"recipient_title":19,"reference_number":19,"action_taken_date":281,"medical_device_id":19,"response_letter_date":19},1750,[268,269,270,252,12,13,13,13],"\u003Ctime datetime=\"2023-11-14T14:20:00Z\">11\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-06T05:00:00Z\">11\u002F06\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaruhan-kimya-ve-temizlik-urunleri-sanayi-ticaret-anonim-sirketi-corlu-subesi-669487-11062023\">Saruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Suleyman Kutluay\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Saruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No: 33-1 Velimese Osb Mahallesi 233 Sokak, E\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>59930\u003C\u002Fspan> \u002F\u003Cspan>Tekirdağ\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Turkey\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-04\u003C\u002Fp>\n\n\u003Cp>November 6, 2023\u003Cbr>\n\u003Cbr>\nDear Mr. Kutluay:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the U.S. Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our June 14, 2022, July 12, 2022, and July 28, 2023 requests for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Saruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi, FEI 3018310083, at No: 33-1 Velimese Osb Mahallesi 233 Sokak, E Tekirdag.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>704(a)(4) Request for Records and Related CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the records and information you provided, you did not demonstrate that you are testing the identity of incoming components used in the manufacture of your drug products. Additionally, you are not testing your incoming lots of ethanol for methanol, which is used to manufacture the hand sanitizers for distribution in the United States.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you perform the identity testing on all raw materials before use in manufacturing. However, you only provided your supplier’s test reports.\u003Cbr>\n\u003Cbr>\nComponent testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your raw materials conform to appropriate specifications before use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Products Containing Ethanol\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol\u003C\u002Fem> at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following for all drug products imported to the United States prior to and after our 704(a)(4) request:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the records and information you provided, you did not demonstrate that you adequately test your OTC finished drug products prior to release for distribution to the United States. Specifically, the COA(s) that you provided did not include identity test results. You also stated that due to the “high alcohol content” in your drug products, you do not perform microbiological tests for your finished drug products.\u003C\u002Fp>\n\n\u003Cp>Full release testing, including for identity, strength, and impurities, must be performed prior to drug release and distribution. Without adequate testing, there is no scientific evidence to assure that your drug products conform to appropriate specifications before release. Please note FDA has encountered microbial contamination of hand sanitizers with high alcohol content.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following for all drug products imported to the United States prior to and after our 704(a)(4) request:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; &nbsp; o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the records and information you provided for stability, you lack an adequate stability testing program and supporting data to show that the chemical properties of your drug products remain acceptable throughout the labeled expiry period of two years. Specifically, you stated that the shelf life of unopened drug product is two years at room temperature and opened drug product should be used within six months. However, you only provided a 2-week test result under accelerated conditions and an 18-month test result under long term conditions. Additionally, these batches were not evaluated for identity.\u003C\u002Fp>\n\n\u003Cp>Without appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following for all drug products imported to the United States prior to and after our 704(a)(4) request:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Stability indicating methods\u003Cbr>\n&nbsp; &nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\n&nbsp; &nbsp; o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>\n&nbsp; &nbsp; o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fp>\n\n\u003Cp>All procedures that describe these and other elements of your remediated stability program\u003Cbr>\n\u003Cbr>\n\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on October 27, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Saruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi at No: 33-1 Velimese Osb Mahallesi 233 Sokak, E Tekirdag into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B) and are misbranded under section 502 of the FD&amp;C Act, respectively.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009675687 and ATTN: Chhaya Shetty.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Suleyman Kutluay\n\nSaruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi\n\nNo: 33-1 Velimese Osb Mahallesi 233 Sokak, E\n\n59930 \u002FTekirdağ\n\nTurkey\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-24-04\n\nNovember 6, 2023\n\nDear Mr. Kutluay:\n\nYour facility is registered with the U.S. Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our June 14, 2022, July 12, 2022, and July 28, 2023 requests for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Saruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi, FEI 3018310083, at No: 33-1 Velimese Osb Mahallesi 233 Sokak, E Tekirdag.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\n\n704(a)(4) Request for Records and Related CGMP Violations\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nBased on the records and information you provided, you did not demonstrate that you are testing the identity of incoming components used in the manufacture of your drug products. Additionally, you are not testing your incoming lots of ethanol for methanol, which is used to manufacture the hand sanitizers for distribution in the United States.\n\nIn your response, you state that you perform the identity testing on all raw materials before use in manufacturing. However, you only provided your supplier’s test reports.\n\nComponent testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your raw materials conform to appropriate specifications before use in the manufacture of your drug products.\n\nDrug Products Containing Ethanol\n\nYou manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\n\nIn response to this letter, provide the following for all drug products imported to the United States prior to and after our 704(a)(4) request:\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and 211.165(b)).\n\nBased on the records and information you provided, you did not demonstrate that you adequately test your OTC finished drug products prior to release for distribution to the United States. Specifically, the COA(s) that you provided did not include identity test results. You also stated that due to the “high alcohol content” in your drug products, you do not perform microbiological tests for your finished drug products.\n\nFull release testing, including for identity, strength, and impurities, must be performed prior to drug release and distribution. Without adequate testing, there is no scientific evidence to assure that your drug products conform to appropriate specifications before release. Please note FDA has encountered microbial contamination of hand sanitizers with high alcohol content.\n\nIn response to this letter, provide the following for all drug products imported to the United States prior to and after our 704(a)(4) request:\n\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\n\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nBased on the records and information you provided for stability, you lack an adequate stability testing program and supporting data to show that the chemical properties of your drug products remain acceptable throughout the labeled expiry period of two years. Specifically, you stated that the shelf life of unopened drug product is two years at room temperature and opened drug product should be used within six months. However, you only provided a 2-week test result under accelerated conditions and an 18-month test result under long term conditions. Additionally, these batches were not evaluated for identity.\n\nWithout appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\n\nIn response to this letter, provide the following for all drug products imported to the United States prior to and after our 704(a)(4) request:\n\nA comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability indicating methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\n\no Detailed definition of the specific attributes to be tested at each station (timepoint)\n\nAll procedures that describe these and other elements of your remediated stability program\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on October 27, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Saruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi at No: 33-1 Velimese Osb Mahallesi 233 Sokak, E Tekirdag into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B) and are misbranded under section 502 of the FD&C Act, respectively.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009675687 and ATTN: Chhaya Shetty.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","Saruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi","saruhan-kimya-ve-temizlik-urunleri-sanayi-ticaret-anonim-sirketi-corlu-subesi-669487-11062023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaruhan-kimya-ve-temizlik-urunleri-sanayi-ticaret-anonim-sirketi-corlu-subesi-669487-11062023","2026-10-26T08:09:54.078363+00:00","2023-11-14","669487","Mr. Suleyman Kutluay","2026-08-20T00:32:03.06+00:00","2023-11-06",14,{"510k":284,"classification":285,"enforcement":286,"event":287,"event_backfill":288,"pma":289,"warning_letter":290},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]